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ABSTRACT 
 
REGULATION OF THE GLUTAMATE/GLUTAMINE CYCLE BY NITRIC OXIDE IN THE 
CENTRAL NERVOUS SYSTEM  
Karthik Anderson Raju 
Harry Ischiropoulos 
 
Nitric oxide (˙NO) is a critical contributor to glutamatergic neurotransmission in the central 
nervous system (CNS).  Much of its influence is due to the ability of this molecule to regulate 
protein structure and function through its posttranslational modification of cysteine residues, a 
process known as S-nitrosylation.  However, little is known about the extent of this modification 
and its associated functional effects in the brain under physiological conditions.  We employed 
mass spectrometry (MS)-based methodologies to interrogate the S-nitrosocysteine proteome in 
wild-type (WT), neuronal nitric oxide synthase-deficient (nNOS-/-), and endothelial nitric oxide 
synthase-deficient (eNOS-/-) mouse brain.  These approaches identified 269 sites from 136 
proteins in the WT brain, with notable reductions in the number of sites detected in either eNOS-/- 
(50% of WT) or nNOS-/- brain (26% of WT).  Gene ontology analysis revealed a cluster of S-
nitrosylated proteins participating in the glutamate/glutamine cycle in wild-type and eNOS-/- mice 
that was underrepresented in nNOS-/- animals, suggesting a role for nNOS-derived ˙NO in the 
regulation of glutamate utilization in the CNS.  Functional profiling of this pathway using 15N-
glutamine based metabolomic analyses and enzymatic activity assays uncovered decreased 
conversion of glutamate to glutamine and increased glutamate oxidation in nNOS-/- mice relative 
to the other genotypes.  Furthermore, site-directed mutagenesis of the rat sodium-dependent 
excitatory amino acid transporter 2 at Cys373 and Cys562 (Cys561 in mouse sequence), the two 
sites of S-nitrosylation observed in wild-type and eNOS-/- mice, revealed inhibition of glutamate 
transport through reversible S-nitrosylation.  The selective, nNOS-dependent S-nitrosylation of 
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proteins that govern glutamate transport and metabolism identifies a previously unknown function 
for ˙NO in glutamatergic neurotransmission. 
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1.1  Introduction 
Since its initial discovery and characterization in the 1980s, nitric oxide (˙NO) 
has become widely accepted as a critical signaling molecule in biological 
function.  Indeed, the field of ˙NO biology owes much to the pioneering work of 
Furchgott, Ignarro, Murad, Moncada, and Hibbs, among others who identified 
roles for ˙NO in vasodilation and immune responses to bacterial infection.  The 
significance of this research was further emphasized by the 1998 Nobel Prize in 
Medicine and Physiology, which recognized ˙NO as a vital signaling intermediate 
in the cardiovascular system (though it was appreciated in other systems as 
well).  ˙NO was initially thought to achieve its effects by binding to the heme iron 
of soluble guanylate cyclase (sGC), resulting in the increased conversion of 
guanosine-5’-triphosphate (GTP) to cyclic guanosine monophosphate (cGMP).  
The ensuing activation of downstream cGMP-dependent signaling cascades 
ultimately lead to physiological changes, such as smooth muscle relaxation.  
However, an alternative mechanism of ˙NO-based regulation was discovered in 
the early 1990s, in which ˙NO could form stable adducts with protein cysteine 
residues to produce S-nitrosocysteine.  The generation of such protein S-
nitrosocysteines was also found to result in physiological changes, including 
vasodilation and platelet inhibition1.  Subsequent studies have reinforced the 
importance of this posttranslational modification (known as S-nitrosylation) as an 
effector of ˙NO-dependent signaling2. 
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Since that initial study in 1992, over 1100 S-nitrosocysteine residues have 
been identified in more than 640 proteins across several cell and organ systems3-
6.  These proteins are involved in a wide array of cellular processes, with S-
nitrosylation implicated as a direct regulator of protein function and subcellular 
localization in multiple targets7-9.  In particular, its physiological and 
pathophysiological contributions to central nervous system (CNS) function have 
elicited intense interest.  Several studies have investigated the regulatory roles of 
S-nitrosylation on specific proteins involved in neurogenesis10, synaptic 
transmission11, and neurodegeneration12.  However, such rigid focus on specific 
targets has led to broader questions concerning the global coordination of 
cellular processes by S-nitrosylation in the brain, especially under physiological 
conditions.  By employing an array of methodologies, ranging from mass 
spectrometry (MS)-based proteomic identification of S-nitrosoproteins to more 
conventional molecular biology and enzymatic approaches, one can start to 
answer at least some of these questions.  In doing so, a greater understanding of 
˙NO’s role in both CNS development and dysfunction can be achieved, while also 
providing valuable preliminary information for future studies. 
1.2  Chemical Properties of Nitric Oxide 
Nitric oxide (also known as nitrogen monoxide) is a gas that was first 
described in 1774 by Joseph Priestly in his Experiments and Observations on 
Different Kinds of Air, Vol. 1.  A diatomic free radical, ˙NO consists of one 
nitrogen and one oxygen atom, with an unpaired valence electron.  Due to both 
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its low solubility in water13 (1.9 mM at 20°C) and liposome/water partition 
coefficient14 of 4.4, ˙NO can diffuse readily through hydrophobic environments 
(including the plasma membrane).  Additionally, it can react with several targets 
to generate a variety of end products15. 
The reactive nature of ˙NO contributes to variations in its half-life, particularly 
through its interactions with oxygen species.  In aqueous solution, ˙NO reacts 
with O2 and possesses a half-life inversely proportional to its concentration16-17.  
In plasma and other physiological buffers, ˙NO oxidation to both nitrite (NO2-) and 
nitrate (NO3-) is facilitated by hemoglobin and other proteins through heme and/or 
other metal chemistries.  The resulting ˙NO metabolites possess an extended 
half-life18-19.  Furthermore, nitric oxide can react with the free radical superoxide 
(O2-) to produce the oxidant peroxynitrite (ONOO-), a reaction that is essentially 
diffusion-rate limited20. 
Metals and lipid-derived radicals can also act as targets of nitric oxide.  Metal 
nitrosyl (M-NO) complexes are readily formed through the coordination of nitric 
oxide to transition metals such as iron and copper21-23, and are important in the 
regulation of a number of enzymes24-25.  Lipid peroxidation is also inhibited by the 
interaction of ˙NO with lipid peroxyl radicals, which can occur at a rate near the 
diffusion limit26-28.  
Taken together, evidence suggests that the biological availability of ˙NO 
(especially as a signaling molecule) is highly dependent on its local environment.  
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Given this information, it is necessary to understand three principles about nitric 
oxide in vivo: how, when, and where it is produced.  Fortunately, these questions 
were answered by a number of landmark studies performed between the 1980s 
and 1990s. 
1.3  Biosynthesis of Nitric Oxide 
The endogenous synthesis of ˙NO was first proposed in a study from 1916, 
which noted a higher nitrate and nitrite concentration in human urine than could 
be accounted for by dietary intake alone29.  This finding was further confirmed by 
isotopic balance experiments utilizing 15NO3-, which revealed that endogenous 
production of nitrate (in this case, without 15N) was the source of excess nitrate in 
urine30.  However, the source of these metabolites remained elusive until 1987, 
when the precursor to both nitrate and nitrate was demonstrated to be L-
arginine31-32.  Specifically, 15N-labeling studies found that the nitrogen in both 
NO2- and NO3- was derived from one of the two guanidino nitrogens in L-arginine, 
while 14C-labeling studies identified L-citrulline as the other product32.  This 
mechanism was further characterized in later reports, with converging lines of 
evidence suggesting ˙NO as an intermediate in the formation of nitrate and 
nitrate33-34. 
Nitric oxide is generated from L-arginine and oxygen, with L-citrulline 
produced as a by-product.  The reaction is catalyzed by three isoforms of the 
enzyme nitric oxide synthase (NOS): NOS1 (neuronal NOS: nNOS), NOS2 
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(inducible NOS: iNOS), and NOS3 (endothelial NOS: eNOS).  Of the three 
isoforms, nNOS was the first to be purified and cloned35-36, with iNOS37 and 
eNOS38-40 following soon afterwards.  Each isoform is a homodimer assembly of 
two 110-150 kDa monomers, composed of an N-terminal oxygenase domain and 
a C-terminal reductase domain linked by a calmodulin recognition site41-42.  The 
oxygenase domain includes binding sites for the cofactors tetrahydrobiopterin 
(BH4) and iron protoporphyrin IX, as well as a binding site for the substrate L-
arginine.  The reductase domain contains binding sites for electron carriers flavin 
mononucleotide (FMN) and flavin adenine dinucleotide (FAD), as well as a site 
for the electron donor NADPH (the reduced form of nicotinamide adenine 
dinucleotide phosphate).  Electrons supplied by NADPH are transported across 
the reductase domain by FAD and FMN to the heme group of iron protoporphyrin 
IX in the oxygenase domain, where they can oxidize L-arginine.  One of the 
guanidino nitrogens in L-arginine undergoes a 5-electron oxidation through two 
mono-oxygenation steps: the first producing Nω-hydroxyarginine (NOHA), which 
is then oxidized to produce L-citrulline and ˙NO43-44.  Calmodulin binding at its 
cognate recognition site is thought to stabilize electron transfer between the 
reductase FMN and the oxygenase heme45. 
All three NOS isoforms are expressed in the brain, and catalyze the 
production of ˙NO from L-arginine and oxygen.  However, they differ in several 
key respects, including functional regulation and levels of ˙NO production.  Both 
nNOS and eNOS are constitutively-expressed NOS isoforms and rely on calcium 
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(Ca2+) to initiate transient bursts of ˙NO synthesis: elevation of intracellular Ca2+ 
stimulates increased binding of calmodulin to both NOS isoforms, leading to the 
generation of ˙NO46-48.  The function of both isoforms is also subject to regulation 
by multiple posttranslational modifications (PTMs), including palmitoylation, 
phosphorylation, S-glutathionylation, and S-nitrosylation49-52.  In contrast, iNOS 
activity is less sensitive to changes in intracellular Ca2+, since the enzyme is far 
more tightly bound to calmodulin to than either nNOS or eNOS37, 53.  Expression 
of this isoform is induced by inflammatory stimuli and results in prolonged periods 
of ˙NO synthesis54-55.  Much less is known regarding its functionally relevant 
PTMs, though it has been found to be S-nitrosylated56.  Of the three isoforms, 
iNOS is thought to generate the highest amounts of ˙NO, with both nNOS and 
eNOS producing orders of magnitude less57-58.   
In addition to the dissimilarities already outlined, the NOS isoforms also differ 
in sequence conservation and localization in the brain.  Analysis of primary 
amino acid sequences for the human NOS enzymes revealed only 51-60% 
homology between the isoforms59.  However, greater sequence homology for 
specific isoforms was conserved between multiple species (>80% for iNOS 
between mouse, rat, dog, and human), suggesting that ˙NO synthesis may be of 
importance in mammalian evolution60.  Given the functional and structural 
diversity of the NOS isoforms, it is interesting to note their restricted expression 
patterns in distinct cell types in the brain. nNOS is primarily expressed in defined 
populations of neurons in the CNS, and associates with specific postsynaptic 
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complexes due to its PDZ domain61-62.  iNOS, on the other hand, is mainly 
expressed in the cytoplasm of astrocytes and microglia during inflammation63-64.  
Finally, eNOS is chiefly expressed in the cytoplasm of both astrocytes and 
vascular endothelial cells in the brain65-67. 
1.4  Nitric Oxide in Physiology 
1.4.1 Identification of Endothelial Nitric Oxide Synthesis 
The long journey in characterizing endogenous biological synthesis of ˙NO 
began in the latter half of the 17th century, with the discoveries of amyl nitrite and 
nitroglycerin as potent vasodilators68-70.  Despite these early studies, the actual 
mechanism of action for these molecules (through the release of ˙NO or ˙NO 
equivalent molecules) remained unknown for close to a century.  In 1977, Ferid 
Murad and colleagues realized that nitrite-containing compounds (including 
nitroglycerin) and ˙NO gas had similar effects in stimulating sGC activity and 
subsequent vascular dilation71, a finding reaffirmed in 1979 by Louis Ignarro’s 
group72.  Robert Furchgott and John Zawadzki made a parallel observation on 
vasodilation in 1980, demonstrating that endothelial cells contributed toward the 
relaxation of smooth muscle73.  By 1982, Furchgott’s team speculated that this 
action was achieved through release of an unstable relaxing substance, referred 
to as endothelial relaxing factor74 (EDRF).  Four years later, both Furchgott and 
Ignarro presented independent findings at a vasodilation symposium suggesting 
that EDRF was actually ˙NO.  In the following year, this hypothesis was 
confirmed by additional findings from Salvador Moncada’s group, who found that 
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endothelium-produced ˙NO derived from L-arginine accounted for EDRF’s 
effects75-76.  Ultimately, the source of endothelial ˙NO was shown to be eNOS38-
40.  Recognition of ˙NO’s importance in vasodilation came in 1998, with the 
awarding of the 1998 Nobel Prize in Medicine and Physiology to Furchgott, 
Ignarro, and Murad. 
In the twenty years since those initial studies, multiple biological 
processes have been found to be regulated by eNOS-derived ˙NO.  Mice with a 
genetic deletion of eNOS (eNOS-/-) exhibit hypertension, hypercoagulability, and 
increased proliferation of vascular smooth muscle cells after vessel injury77-79.  
Additionally, they demonstrate greater leukocyte/endothelium interaction, 
increased infarct size after middle cerebral artery occlusion (MCAO), and 
decreased beta-oxidation of fatty acids through very long chain acyl-CoA 
dehydrogenase8, 80-81.  Modulation of eNOS activity through phosphorylation at 
serine 1176 has been shown to affect insulin sensitivity, regulation of insulin 
levels, adiposity, and vascular reactivity82-83.  Considered as a whole, the data 
implicates eNOS-derived ˙NO in the global coordination of vascular and 
metabolic function.   
1.4.2 Nitric Oxide Synthesis and the Immune Response 
Prior to Moncada’s findings, John Hibbs and colleagues identified L-
arginine as an essential substrate for nitrite synthesis following macrophage 
activation31.  In doing so, they provided one of the first examples for endogenous 
10 
 
biosynthesis of nitric oxide (though this was not recognized until later).  
Metabolism of L-arginine by macrophages was necessary for their cytotoxic 
activity against target tumor cells84.  However, the generation of ˙NO as an 
intermediate in this process was not established until a series of studies 
published between 1988 and 198933, 85-86.  Consequently, the involvement of ˙NO 
in several inflammatory cascades has been described87-90.  Nitric oxide has been 
shown to decrease cellular respiration through disruption of iron-sulfur clusters in 
the electron transport chain91.  Moreover, it can affect membrane potential 
maintenance, DNA repair, lipid peroxidation, and other critical functions in target 
cells92-94. 
Eventually, the chief source of ˙NO in macrophages and other immune 
cells was found to be iNOS37, which is upregulated in response to inflammatory 
cytokines and other stimuli.  Mice with a genetic deletion of iNOS (iNOS-/-) are 
phenotypically similar to wild-type (WT) mice under normal conditions.  However, 
they are more susceptible to parasitic infection, bacterial proliferation, and 
intestinal tumorigenesis95-98.  Concomitantly, they are resistant to sepsis-induced 
hypotension, inflammation-induced osteoporosis, and ischemia-induced 
neurodegeneration in the brain96, 99-101.  Taken together, the evidence suggests 
iNOS-derived ˙NO as a local inducible regulator of the immune response to 
pathogens and cellular damage. 
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1.4.3 Nitric Oxide and the Central Nervous System 
Given its systemic nature as a signaling molecule, it is no surprise that 
nitric oxide also influences brain physiology.  Early studies in the cerebellum 
implicated ˙NO synthesis as an intermediate step between N-methyl-D-aspartate 
(NMDA) receptor stimulation by glutamate and cGMP synthesis102-103.  In doing 
so, they provided a first glimpse into nitric oxide’s role in neurotransmitter signal 
transduction. These findings were later followed up by multiple observations of 
˙NO’s contribution to long-term potentiation (LTP), a measure of synaptic 
plasticity104-108.   
 Subsequent investigations have identified nitric oxide as a critical 
participant in several biological processes in the CNS.  Presynaptic vesicular 
release and recycling is potentiated by nitric oxide through increased SNARE 
complex assembly and regulation of phosphatidylinositol 4, 5-biphosphate 
(PIP2)-dependent processes109-111.  Exoendocytic coupling and glutamate/GABA 
release during neurotransmission is facilitated by ˙NO-based activation of 
presynaptic hyperpolarization-activated cyclic nucleotide-gated (HCN) channels 
and protein kinase G112-116 (PKG).  Similarly, presynaptic remodeling is 
accomplished through ˙NO-dependent kainate receptor recruitment and activity-
dependent synaptogenesis117-119.  On the postsynaptic side, ˙NO has been 
shown to modulate target neuron excitability through regulation of Kv2/Kv3 
potassium channel activity and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptor trafficking120-122.  Finally, ˙NO-dependent upregulation of 
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glycolysis in astrocytes has been shown to be important in supporting changes in 
neuronal activity123-124. 
Much of the work documenting ˙NO’s effects on the CNS was only made 
possible by the initial purification and characterization of nNOS, the first NOS 
isoform to be isolated35-36.  In particular, discovery of postsynaptic tethering 
between the NMDA receptor, PSD-95, and nNOS provided a molecular 
explanation for the association between synaptic transmission and ˙NO 
production/activity62, 125.  Upon presynaptic release of glutamate into the synaptic 
cleft, it is free to bind to the postsynaptic NMDA receptor (along with a receptor 
co-agonist, either glycine or D-serine).  Once activated, the NMDA receptor 
allows Ca2+ to enter the neuron.  Due to the close proximity of the NMDA 
receptor to nNOS afforded by the PSD-95 scaffold, this Ca2+ influx subsequently 
leads to ˙NO synthesis.   
Predictably, loss of nNOS has profound effects on CNS function.  Mice 
with a genetic deletion of this isoform (nNOS-/-) demonstrate substantially 
decreased NO production (>90%) relative to WT mice126.  Consequently, they 
exhibit a number of phenotypic deficits, including impairments in various forms of 
recognition, fear conditioning, working memory, and other cognitive functions127-
130.  Many, if not all, of these insufficiencies may be symptomatic of widespread 
synaptic dysfunction across the brain: several reports have documented 
decreases in both synaptic potentiation and depression in these mice relative to 
WT animals131-132.  Correspondingly, nNOS-/- mice also demonstrate an 
13 
 
attenuated cerebral blood flow response to increased synaptic activity, 
suggesting a local influence for nNOS-derived ˙NO beyond the specific 
coordination of presynaptic and postsynaptic neurons133. 
 In addition to the physiological effects of nNOS-derived ˙NO observed in 
the CNS, a number of pathophysiological effects have also been identified in 
recent years.  Most prominently, dysfunctional ˙NO production by nNOS is 
heavily implicated in the pathological progression of cerebral ischemia.  
Disruption of PSD-95/nNOS coupling has been shown to be neuroprotective after 
MCAO in rodents, a finding consistent with the reduced cell death seen in nNOS-
/- mice after MCAO134-135.  Similarly, in an MPP+ model of dopaminergic 
neurodegeneration, genetic deletion or pharmacological inhibition of nNOS 
proved effective in preserving neuronal viability136-137.  Indeed, excessive nNOS 
activity is implicated in the abnormal regulation of a number of different proteins 
that contribute to neurodegeneration, including peroxiredoxin-2138 (Prx2), X-
linked inhibitor of apoptosis12 (XIAP), glyceraldehyde-3-phosphate 
dehydrogenase7 (GAPDH), and parkin139.  Much of this disproportionate 
synthesis of ˙NO may be due to the high levels of extracellular glutamate present 
after initial cellular degeneration the CNS: the resultant stimulation of surrounding 
neuronal NMDA receptors could activate nNOS into producing 
supraphysiological levels of ˙NO in response140.  Considered as a whole, the 
evidence indicates that the difference between physiological and 
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pathophysiological function in the CNS may be regulated, at least in part, through 
nNOS-derived ˙NO. 
1.5  Mechanisms of Nitric Oxide-Based Signaling 
1.5.1 Activation of sGC/cGMP Cascades 
Soluble guanylate cyclase (sGC) is one of two main subtypes of the 
guanylyl cyclase enzyme, which is responsible for catalyzing the production of 
cGMP and pyrophosphate from GTP.  Three subunits of the enzyme have been 
identified: α1, α2, and β1.  A functional complex of the enzyme consists of a 
heterodimer of α and β subunits, resulting in two isoforms of sGC: α1β1 and α2β1.  
Both isoforms are expressed in the brain, and exhibit regional differences in 
expression: α1β1 is more prominent in the caudate/putamen and nucleus 
accumbens, while α2β1 is expressed at higher levels in the hippocampus and 
olfactory bulb141-142. 
Nitric oxide acts on sGC through direct binding to the N-terminal heme-
containing domain of the enzyme’s β1 subunit.  The heme group of sGC shows 
exquisite sensitivity for ˙NO over O2, with the ability to detect ˙NO in the presence 
of a 10,000-fold excess of O2 and an EC50 for ˙NO between 1-2 nM143-144.  One of 
the current models postulates that binding of ˙NO to the heme group leads to the 
release of an Fe2+-ligated histidine residue from the heme group, leading to 
conformational changes in the enzyme that are transduced to the catalytic 
domain.  Subsequently, this allows for the binding of other ˙NO molecules to 
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lower-affinity sites on the protein, and results in significantly upregulated cGMP 
production145.  Presynaptically, ˙NO synthesis and subsequent sGC activity is 
primarily initiated by action potential-dependent Ca2+ flux through N-type 
channels146.  Postsynaptic sGC activity is chiefly dependent on NMDA receptor-
mediated Ca2+ flux, due to its association through PSD-95 to both the NMDA 
receptor and nNOS147.   
˙NO-dependent changes in cGMP production are vital in mediating 
downstream biological processes in the CNS.  For example, they can regulate 
Na+, Ca2+, and K+ flux though CNG and HCN channels, thereby modulating 
neuronal excitability147-148.  Additionally, they can lead to autoregulation of cyclic 
nucleotide levels through the activation of specific phosphodiesterases (including 
PDE2, PDE5, and PDE6), leading to reductions in cAMP/cGMP signaling149.  
Alternatively, ˙NO can exert its effects on cGMP signaling cascades through the 
regulation of cGMP-dependent protein kinase (PKG) activity.  This process has 
been implicated in a variety of different functions in the CNS, including vesicular 
GABA release112, K+ flux through Kv1.1/1.2 channels150, ryanodine receptor 
(RyR)-dependent Ca2+ release from internal stores151, and other pathways152. 
Despite the evidence supporting cGMP signaling as a relevant ˙NO 
effector, it was soon recognized that it was not the only pathway available for 
˙NO-dependent regulation of biological function.  Inhibition of cGMP synthesis did 
not completely block many of the ˙NO-dependent effects observed in brain 
physiology, indicating a yet-undiscovered regulatory avenue by ˙NO that 
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extended beyond phosphorylation-dependent signaling cascades153-156. 
Eventually, this led to the identification of S-nitrosylation as another mechanism 
through which ˙NO could influence protein structure and function. 
1.5.2 Protein S-Nitrosylation 
S-nitrosothiols were first identified by Tasker and Jones in 1909, after 
treatment of ethane-thiol with nitrosyl chloride157.  The biological utility of this 
chemical species was not noted until a series of studies by Ignarro and 
colleagues in the 1980s, which demonstrated novel properties for S-nitrosothiols 
in smooth muscle relaxation and anti-platelet aggregation158-159.  These effects 
were initially attributed to the activation of sGC by ˙NO released from the thiol.  
However, by 1990 Kowaluk and Fung concluded that a number of the bioactive 
effects of S-nitrosothiols could not be solely accounted for by decomposition to 
˙NO160.  These findings were soon extended by Stamler and colleagues in 1992, 
who found that protein thiols could undergo the transformation to S-nitrosothiols 
under physiological conditions and thereby extend the half-life of ˙NO: the 
resultant S-nitrosoproteins also possessed vasodilatory and platelet aggregation 
effects1, similar to EDRF/˙NO.  Subsequent identification of endogenous S-
nitrosoalbumin in blood plasma confirmed the in vivo biosynthesis of S-
nitrosoproteins, and opened up a new field of ˙NO biology for further study161. 
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1.5.2.1 Mechanisms of Protein S-Nitrosylation and De-Nitrosylation 
Several biochemical mechanisms of protein S-nitrosocysteine formation (Prot-
SNO) have been proposed, both nonenzymatic and enzymatic.  The first involves 
the autooxidation of ˙NO through its reaction with O2, resulting in the generation 
of a series of nitrogen oxides162. 
1) ˙NO + O2  ONOO 
2) ONOO + ˙NO  N2O4 
3) N2O4  2˙NO2 
4) ˙NO2 + ˙NO  N2O3 
5) N2O3 + Prot-SH  Prot-SNO + H+ + NO2- 
N2O3 is considered a potent nitrosating agent, and is thought to react with protein 
thiols (Prot-SH) to generate protein S-nitrosocysteine.  The rate constant for 
N2O3 formation in aqueous environments (2-5 x 106 M-2 s-1) is thought to render it 
impractical under physiological conditions, due to the rate-limiting formation of 
NO217, 163-166.  Despite this limitation, it may be favored in localized cellular 
compartments, due to a few key factors.  The reaction rate for N2O3 generation is 
very sensitive to reactant concentration, especially that of ˙NO.  Additionally, the 
rate constant for the reaction can increase up to 300-fold in hydrophobic 
environments such as biological membranes167-169.  Given the lipophilic nature of 
˙NO, both of these requirements may be met at sufficient enough levels in 
compartmentalized membrane environments to generate local nitrosating 
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species170.  Alternatively, another mechanism for S-nitrosylation relies on the 
generation of protein thiyl radical (Prot-S˙) from the reaction between NO2 and a 
cysteine thiol171. 
1) NO2 + Prot-SH  Prot-S˙ + H+ + NO2- 
2) ˙NO + Prot-S˙  Prot-SNO 
However, this process still relies on the rate-limiting formation of NO2, leaving it 
with the same restrictions as N2O3. 
 A second demonstrated mechanism for protein S-nitrosylation depends on 
the direct reaction of ˙NO with a transition metal (Me(n+1)+), such as Fe3+ or Cu2+.  
This results in the reduction of the metal, as well as the generation of a 
nitrosonium (NO+) ion, at rates more physiologically relevant than those observed 
for NO2/N2O3 formation.  The nitrosonium, subsequently, is free to react with 
local cysteine thiols172-174. 
1) Me(n+1)+ + ˙NO  Me(n)-NO+ 
2) Me(n)+-NO+ + Prot-SH  Prot-SNO + Me(n)+ + H+ 
Another related mechanism for protein S-nitrosylation relies on the generation of 
dinitrosyl-iron complexes from ˙NO and free iron pools, which can then lead to 
subsequent protein S-nitrosylation175-177. 
 A third mechanism of protein S-nitrosylation involves the reversible 
transfer of a nitrosonium group between cysteine thiols, referred to as trans-
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nitrosylation.  The source of the nitrosonium can be either a low molecular weight 
S-nitrosothiol, such as S-nitrosoglutathione (GSNO), or another protein S-
nitrosocysteine (the second scenario is referred to as protein-assisted trans-
nitrosylation: this includes protein de-nitrosylation as well). 
1) Prot-SH + GSNO ↔ GSH + Prot-SNO 
2) Prot1-SNO + Prot2-SH ↔ Prot1-SH + Prot2-SNO 
Intracellular pools of glutathione (GSH) and GSNO are major endogenous 
sources of nitrosonium acceptors and donors, respectively161, 178-181.  Together 
with existing protein thiols and S-nitrosothiols, they provide the substrates 
necessary for the regulation of cellular processes. 
The biosynthetic mechanisms underlying intracellular GSNO formation under 
aerobic conditions remain unclear, although it may require either ˙NO 
autooxidation to N2O3 or the reaction of ˙NO with a glutathionyl radical (GS˙).  
Alternatively, it may be generated through the generation of a thionitroxide 
intermediate182 (GSNO-H), which can then reduce molecular oxygen and result in 
superoxide (O2-) and GSNO. 
1) GSH + ˙NO  GSNO-H 
2) GSNO-H + O2  GSNO + O2- 
GSNO levels are maintained by several different enzymes, such as S-
nitrosoglutathione reductase (GSNO-R), carbonyl reductase 1 (CR1), thioredoxin 
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(Trx), and γ-glutamyl transpeptidase (γ-GT).  In doing so, they may indirectly 
influence protein S-nitrosylation in a number of different tissues through the 
regulation of available nitrosonium from GSNO183-186. 
 Protein-assisted trans-nitrosylation represents an additional avenue of 
˙NO-dependent signal transduction, though one that remains relatively 
unexplored.  One of the first trans-nitrosylation-dependent “cascades” described 
involves the regulation of caspase-dependent cell death by thioredoxin.  
Thioredoxin modulates the Fas-induced activation of caspase-3 through trans-
nitrosylation/de-nitrosylation of caspase-3, with caspase de-nitrosylation a 
prerequisite for apoptosis185, 187.  Similarly, GAPDH-mediated trans-nitrosylation 
of Siah has been identified as a key contributor to neuronal apoptosis7, 188.  A 
third recently elucidated pathway involves the assembly of proteins in the 
interferon-gamma (IFN-γ)-activated inhibitor of translation (GAIT) complex, a 
process dependent on S100A9-mediated trans-nitrosylation189.  Additional 
studies have identified candidate de-nitrosylases in the regulation of cellular S-
nitrosothiol levels, including protein disulfide isomerase, xanthine oxidase, 
superoxide dismutase, and glutathione peroxidase190-193.  Given the large 
number of S-nitrosoproteins already identified, these pathways may only 
represent a small fraction of the trans-nitrosylation-dependent processes 
involved in physiological function. 
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1.5.2.2 Selectivity of S-Nitrosylation 
  Although significant progress has been made in identifying the protein 
substrates of S-nitrosylation, the selectivity behind the endogenous modification 
of specific cysteine residues is not as well-described.  Several attempts have 
been made to decipher the biophysical and biochemical requirements behind in 
vivo S-nitrosylation of cysteine residues with mixed results.  Analysis of protein 
S-nitrosocysteines identified in the WT mouse liver found them to be 
overrepresented in α-helical structures, with locations in larger surface-
accessible areas and proximal (within a 6-A radius) to charged amino acids194.  
However, these structural characteristics could not account for all S-
nitrosocysteines identified, a finding confirmed in a later survey of S-
nitrosocysteines identified in multiple mouse organs4-5.  Additional studies have 
indicated that charged residues distal to specific cysteine residues could 
participate in protein-protein interactions that may facilitate S-nitrosylation of 
those cysteine residues, with proximal acid/base motifs thought to play a role in 
this process as well195-196.  S-nitrosocysteines have also been found near metal 
centers of proteins176, 197-198, a fact that may be important given the known ability 
of certain transition metals to coordinate to ˙NO.  Recently, a I/L-X-C-X2-D/E 
motif for protein trans-nitrosylation has been discovered in members of the GAIT 
complex189, which become S-nitrosylated by iNOS-derived ˙NO in response to 
IFN-γ and oxidized low-density lipoprotein (LDLOX).  When considered as a 
whole, the evidence suggests that multiple mechanisms may be involved in the 
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selectivity of S-nitrosocysteine formation in proteins.  This, in turn, would result in 
the diverse subset of S-nitrosoproteins detected thus far. 
1.5.2.3 S-Nitrosylation and Protein Function in the CNS 
 As an alternative pathway for ˙NO-dependent cell signaling, S-nitrosylation 
has garnered intense interest in the CNS.  A survey of prior reports has yielded 
more than 170 proteins with 323 S-nitrosocysteine residues in vivo in rodent 
brain.  Of these proteins and sites, only 120 proteins with 181 sites were found 
under physiological conditions, suggesting a biased association in the literature 
between S-nitrosylation and cell death in the brain.  On the other hand, additional 
roles have also been observed for protein S-nitrosylation in neuronal 
development and synaptic transmission.  Collectively, the existing information 
suggests a functional pleiotropy for this modification during both normal 
physiology and disease in the CNS, similar to phosphorylation or acetylation199-
200. 
 Several groups have focused on the contributions of S-nitrosylation of 
specific protein targets to neurodegeneration.  These include, among others, the 
inhibition of parkin E3 ubiquitin ligase activity139, GAPDH-induced apoptosis7, 201, 
caspase activation via XIAP inhibition12, PTEN-dependent regulation of PI3/Akt 
signaling202, and MEF2-mediated transcriptional regulation10.  The widespread 
effects of S-nitrosylation in multiple processes, ranging from transcriptional 
repression of specific genes to perturbations in numerous cell survival pathways, 
imply a large contribution from ˙NO to the pathological effects observed in many 
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chronic neurological disorders (such as Alzheimer’s or Parkinson’s disease).  
Despite such findings, however, it is the effects of endogenous S-nitrosylation on 
physiological function that are gaining recognition for their importance in refining 
and maintaining critical biological processes within the brain. 
  In recent years, the significance of this modification in normal CNS 
development has become increasingly apparent.  S-nitrosylation of transcription 
factor MEF2A prevents it from binding to specific promoters, leading to 
decreased expression of the nuclear receptor tailless and subsequent 
impairments in neurogenesis and neuronal differentiation10.  Transduction of the 
BDNF/CREB-dependent signaling cascade is achieved through the S-
nitrosylation of effector molecules, including sirtuin-1 (SIRT1) and histone 
deacetylase 2 (HDAC2), resulting in gene expression changes that affect 
neuronal differentiation and axodendritic morphology201, 203-204.  Furthermore, 
axonal retraction is partly guided via S-nitrosylation of the light chain of 
microtubule-associated protein 1B (MAP1B), thereby affecting growth cone 
dynamics during CNS maturation205.  Given this evidence, a case can be made 
for protein S-nitrosylation as a “synaptic tag”, linking neuronal signaling (via 
glutamate and postsynaptic ˙NO production by nNOS) to longstanding changes 
in synaptic plasticity206. 
Perhaps most interesting are the documented effects of S-nitrosylation on 
protein function at the synapse itself.  It regulates cation flux through NMDA207 
and AMPA208 receptors, as well as the attachment of scaffold protein PSD-95 to 
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the postsynaptic plasma membrane11.  Additionally, it governs postsynaptic 
AMPA receptor trafficking209-210 and gephyrin clustering211 in response to 
glutamatergic and GABAergic activity, respectively.  Finally, D-serine production 
is decreased by S-nitrosylation of serine racemase212, leading to its reduced 
availability as a coagonist for synaptic NMDA receptor activation213.  Taken 
together, these data suggest S-nitrosylation as a potent coordinator of both short-
term and long-term responses to synaptic transmission.  However, since 
previous reports of the modification in the CNS primarily focused on analyses of 
single proteins, investigation of this hypothesis may be better aided by large-
scale in vivo proteomic identification of endogenously S-nitrosylated proteins 
from the brain.  Most of the approaches developed thus far for such studies are 
outlined in the next chapter.  Moreover, it leads to the central questions of our 
study in Chapter 3, namely: 
1) Which targets of S-nitrosylation in the brain are involved in the regulation 
of synaptic function? 
2) What is the source of ˙NO utilized for the modification of these proteins 
(this may also contribute to spatial localization/modification of these 
proteins)? 
3) What are the functional effects of this modification in these proteins, and 
how do they contribute to neurotransmission as a whole?  
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Abstract 
A biochemical pathway by which nitric oxide accomplishes functional diversity is 
the specific modification of protein cysteine residues to form S-nitrosocysteine.  
This post-translational modification, S-nitrosylation, impacts protein function and 
location.  Despite considerable advances with individual proteins, the biological 
chemistry and the structural elements that govern the modification of specific 
cysteine residues in vivo are vastly unknown.  Moreover comprehensive studies 
exploring protein signaling pathways or interrelated protein clusters that are 
regulated by S-nitrosylation have not been performed on a global scale.  To 
provide insights to these important biological questions, sensitive, validated and 
quantitative proteomic approaches are required.  This review summarizes current 
approaches for the global identification of S-nitrosylated proteins.    
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Highlights 
• S-nitrosylation of cysteine residues an important regulator of protein 
function 
• Description of methods to identify S-nitrosylated proteins 
• Mass spectrometry-based proteomics essential for further studies of S-
nitrosylation biology 
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2.1 Introduction 
Since its discovery nitric oxide has become increasingly evident as a 
major regulator of physiological function.  The effects of nitric oxide on physiology 
are exerted primarily through two molecular mechanisms, comprised of cyclic 
GMP (cGMP)-dependent signaling cascades and post-translational modification 
(PTM) of proteins.  Initially, nitrosylation of the heme iron in soluble guanylate 
cyclase was found to activate the enzyme to generate cGMP, thereby regulating 
the function of a number of cGMP-dependent signaling pathways.  However, in 
recent years the importance of nitric oxide-derived post-translational 
modifications of proteins has gained recognition as mediators of protein function. 
One of these modifications, S-nitrosylation, is defined as the covalent 
addition of a nitric oxide equivalent to the thiol side chain of cysteine [1].  This 
modification has been shown to alter protein activity, protein-protein interactions, 
and sub-cellular localization under physiological and pathological conditions [2, 3, 
4, 5].  Additionally, evidence indicates that S-nitrosylation is reversible and is 
regulated in a temporal and spatial sense, reminiscent of other post-translational 
modifications such as phosphorylation [6, 7, 8].  Despite these indications of the 
emerging significance of S-nitrosylation, little is known regarding the proximal 
mechanisms of in vivo formation as well as how selectivity, in terms of directing 
modification to specific cysteine residues, is achieved.  To improve our 
understanding of the formation and selectivity of this post-translational 
modification in vivo, global interrogation of S-nitrosoproteomes can be 
exceptionally valuable.  Below we review the methodologies for the global 
identification of S-nitrosylated proteins (Table 2.1), and discuss potential utilities 
of proteomic-derived data.   
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2.2   The Biotin Switch and Its Variations 
2.2.1   The Biotin Switch 
The biotin switch [9] was the first and is the most commonly used 
technique for identifying S-nitrosylated proteins.  Three steps constitute the basic 
principles of the method: 1) initially, proteins in a purified preparation or complex 
mixture are denatured by SDS (or urea, which is more amenable to downstream 
mass spectrometry analysis, 10); to expose protein cysteine residues.  
Subsequently, the reduced thiols in these proteins are blocked by reaction with 
reagents such as methyl methanethiosulfonate (MMTS), N-ethylmaleimide 
(NEM), or iodoacetic acid (IAA).  2) Following this blocking step, S-nitrosylated -
cysteine residues are selectively reduced by treatment with ascorbate.  3) The 
ascorbate-reduced cysteine residues are then reacted with biotin-HPDP (N-[6-
(biotinamido)hexyl]-3’-(2’-pyridyldithio)-propionamide).  The conjugation of these 
protein cysteine residues to biotin permits enrichment of the modified targets 
from a complex mixture using avidin-based affinity capture.  The affinity enriched 
preparations can be probed with antibodies, if the protein targets of interest are 
known, or digested with trypsin and subjected to liquid chromatography tandem 
mass spectrometry (LC-MS/MS).  One added benefit of this method is that it is 
amenable to stable isotope labeling with amino acids in cell culture (SILAC) in 
order to quantitatively determine the levels of S-nitrosylation for specific cysteine 
residues via mass spectrometry-based approaches [11]. 
 
2.2.2   Biotin Switch-based Peptide Identification 
The original biotin-switch method did not provide the means to identify the 
site(s) of modification in S-nitrosylated proteins.  Identification of these sites is 
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the ultimate qualifier for the unambiguous assignment of S-nitrosylated proteins.  
Site-specific identification enables mutational analysis to explore the functional 
role of this modification.  Two similar approaches to achieve site-specific 
identification of modified cysteine residues have been developed based on the 
biotin switch [12, 13].  For both methods, proteins are first digested with trypsin 
and the resultant peptides are incubated with avidin or its derivatives.  These 
peptides are then eluted and subjected to LC-MS/MS to determine the site of 
modification. 
 
2.2.3   The His-Tag Switch 
Since the original description of the biotin switch methods, several 
variations have been developed.  One of these variants, the His-Tag switch, [14] 
begins with the blocking of free thiols by NEM, followed by ascorbate reduction of 
S-nitrosylated cysteine residues.  It diverges from the biotin switch, however, by 
treating these ascorbate-reduced cysteines with a conjugate of iodoacetate and a 
His-containing peptide.  Proteins containing this “His-tag” are then enriched 
through affinity chromatography in a nickel column, after which they are eluted 
and subjected to 1-dimensional (1D) gel electrophoresis.  In-gel digestion with 
trypsin is then performed.  Trypsin, in addition to cleaving the peptide backbone 
also facilitates cleavage of part of the alkylating agent, resulting in a mass 
increase of the cysteine residue by 271.12 Da, which is used to identify the 
modified peptide by LC-MS/MS.  This method thus provides another approach for 
identifying the site(s) of modification in S-nitrosylated proteins. 
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2.2.4   Fluorescence-based Detection (DyLight, Cyanine, and AMCA-based 
Methods) 
Another method based on the biotin switch relies on 2-dimensional 
differential gel electrophoresis (2D-DIGE, 15).  The initial steps of this approach 
are identical to the biotin switch.  After blocking by MMTS (or NEM) S-
nitrosylated-cysteine residues are reduced by ascorbate.  However, instead of 
biotin-HPDP, a set of DyLight maleimide sulfhydryl reactive fluorescent 
compounds are used to react with the newly reduced cysteine residues.  
Individual samples labeled with a DyLight fluorescent compound are separated 
on a 2D gel.  By comparing the fluorescent intensity of a single spot in the gel, a 
relative assessment of protein S-nitrosylation levels can be made.  Another 
variation of this method employs fluorescent cyanine maleimide sulfhydryl 
reactive compounds instead of the DyLight compounds [16]. 
An additional iteration of this “fluorescence switch” utilizes 7-amino-4-
methyl coumarin-3-acetic-acid (AMCA)-HPDP to label S-nitrosylated cysteine 
residues after ascorbate reduction [17].  In this method, samples are resolved on 
either 1D or 2D gels after labeling.  Subsequently, the gel is subjected to UV 
illumination, which activates the AMCA fluorophore and allows it to be directly 
visualized.  All three versions of the “fluorescence switch” method allow for 
relative quantification of S-nitrosylation levels of proteins between samples 
through comparison of fluorescent intensities.  However, in each case the site(s) 
of S-nitrosylation in specific proteins remains elusive, thereby rendering further 
studies of the functional impact of this modification challenging. 
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2.2.5   d-Switch 
In addition to the capabilities offered by a combination of SILAC labeling 
and the biotin switch, another quantitative method was developed and tested in a 
purified protein preparation [18].  In this technique, reduced cysteine residues in 
recombinant glutathione S-transferase P1 (GST-P1) are labeled with NEM.  S-
nitrosylated cysteine residues in GST-P1 are then subjected to ascorbate 
reduction, followed by treatment with deuterated (d5)-NEM and in-gel trypsin 
digestion.  Mass spectrometry is then used to determine the relative amounts of 
peptides containing only d5-NEM versus those containing both d5-NEM and NEM, 
providing a quantitative assessment of S-nitrosylation. 
 
2.2.6   SNO-RAC 
Recently, another approach was developed by Stamler and colleagues to 
enrich for S-nitrosylated proteins from a complex mixture [19].  Referred to as 
“SNO-RAC,” this method relies on the conjugation of reduced cysteine residues 
to a solid support, such as thiopropyl sepharose.  The first two steps of the 
protocol are identical to the biotin switch.  However, the ascorbate-reduced 
cysteine residues are incubated with thiol-reactive resins, resulting in a covalent 
disulfide linkage.  At this point, the proteins can be eluted and analyzed by 
western blotting.  Alternatively, the disulfide linkage allows for on-resin trypsin 
digestion of bound proteins, resulting in site-specific identification of modified 
cysteine residues by LC-MS/MS.  Compared to the traditional biotin switch, SNO-
RAC has a better sensitivity for proteins with higher mass (>100 KDa).  When 
combined with iTRAQ labeling, it can also report on the S-nitrosylation/de-
nitrosylation of specific cysteine residues on a global scale [20].   
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2.2.7   Overview of the Biotin Switch-based Methods 
Application of the biotin switch method and its various iterations to the 
identification of endogenously S-nitrosylated proteins (defined here as proteins in 
cell lysate or tissue homogenate without nitric oxide or trans-nitrosylating donor 
treatment) has yielded 135 targets from multiple organs and cell types.  Within 
this subset of proteins, 82 sites have been reported from 63 proteins, illustrating 
the importance of the biotin switch in exploring the S-nitrosoproteome.  However, 
three potential issues have been discussed with regard to these methods.  First, 
the efficiency/sensitivity of this assay relies on complete blocking of reduced 
cysteine residues.  Incomplete blocking will result in false identification, which 
can be minimized by the inclusion of negative controls such as pretreatment with 
ultraviolet (UV) photolysis or dithiothreitol (DTT).  Second, the efficiency of 
ascorbate reduction has been questioned [21, 22, 23], suggesting decreased 
sensitivity of the method.  The concerns over ascorbate reduction are 
compounded by its potential ability to reduce disulfides [24, 25], leading to false 
identification.  Again, the inclusion of negative controls (listed above) as well as 
samples not treated with ascorbate can be employed.  Alternatively, sinapinic 
acid has been used to treat cell lysates in place of ascorbate as a more selective 
method of reducing S-nitrosylated cysteine residues [26].  Third, there is the 
possibility of disulfide exchange after ascorbate reduction, leading to false 
identification of modified cysteine residues [20].  The use of methods that rely on 
a direct reaction with S-nitrosylated residues without requiring ascorbate 
reduction may overcome this concern.  Taken together, these potential 
methodological challenges stimulated the development of alternative approaches 
for exploring the S-nitrosoproteome.   
48 
 
2.3   Direct Detection of S-nitrosylation by Mass Spectrometry 
Theoretically, many of the concerns noted with the biotin switch and other 
chemical derivatizations can be avoided by direct detection of S-nitrosocysteine 
by mass spectrometry.  In practice, such an approach remains challenging and 
has been possible primarily for isolated proteins.  Certain MS approaches such 
as matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS, 
where the energy needed for peptide ionization also causes the loss of nitric 
oxide from the cysteine residues, can be employed.  The reduction in mass by 29 
Da in peptides after ionization is then diagnostic of S-nitrosylated sites.  Within 
the last five years, a few groups [27, 28] have been able to directly identify S-
nitrosylated cysteine residues by electrospray ionization quadrupole time-of-flight 
(ESI-QTOF) MS.  However, such investigations were limited to synthetic proteins 
and/or peptides, or were only able to identify a few sites of S-nitrosylation from a 
complex mixture, rendering them unsuitable in their current form to proteome-
wide identification of S-nitrosylated protein targets. 
 
2.4   Gold Nanoparticle-based Enrichment 
A method that relies on a direct reaction of S-nitrosocysteine residues with 
gold nanoparticles (AuNPs) has been developed for identifying sites of S-
nitrosylation in purified protein preparations [29].  In this method, reduced 
cysteine residues are initially alkylated by iodoacetamide (IAM), after which the 
protein is subjected to proteolysis.  Following this digestion, peptides are 
incubated with AuNPs to selectively react with the S-nitrosylated cysteine 
residues, generating free nitric oxide and peptides conjugated to the AuNPs.  
The nanoparticles are then treated with DTT to elute bound peptides, which are 
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subsequently analyzed by mass spectrometry to identify sites of modification.  
Despite the potential advantages offered by this method, two drawbacks exist.  
First, the AuNPs react with both S-nitrosylated and S-glutathionylated cysteines, 
providing a challenge for absolute assignment of specific post-translational 
modifications to these residues.  Second, this approach has not yet been applied 
to complex mixtures.  Nonetheless, it holds excellent promise for site-specific 
identification of modified cysteine residues in S-nitrosylated proteins.    
 
2.5   Phosphine-based Direct Labeling of S-Nitrosylated Proteins 
To overcome the reliance of previous methods on the complete blocking 
of reduced cysteine residues (either by MMTS, NEM, or other reagents), Zhang 
and colleagues [30] introduced another approach to directly label S-nitrosylated 
cysteine residues in cell extracts.  For this particular method, S-nitrosylated 
cysteine residues are reductively ligated (in the presence of water) with a biotin-
labeled phosphine substrate, resulting in the generation of a sulfenamide product 
and thiolate.  The sulfenamide and thiolate then spontaneously react to provide a 
stable disulfide (conjugated to biotin) at the formerly S-nitrosylated cysteine 
residue.  Avidin-based enrichment of these labeled proteins is performed, and 
captured proteins are then resolved on a 1D gel.  This particular approach is 
advantageous in its reactive specificity toward S-nitrosylated cysteine residues in 
the absence of blocking.  Following the introduction of this method, a number of 
phosphine-based compounds have been developed that directly react with S-
nitrosylated -cysteine residues [31, 32, 33].  Although these approaches have yet 
to identify endogenously modified sites, these compounds offer intriguing 
possibilities to explore protein S-nitrosylation in vivo. 
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2.6  Organomercury-Based Capture 
After considering some of the limitations inherent in the biotin switch 
technique and its successors, we introduced novel complementary methods for 
capturing S-nitrosylated proteins and identifying their sites of modification [34].  In 
this protocol, phenylmercury compounds (either conjugated to an agarose solid 
support or to polyethylene glycol-biotin) react directly with S-nitrosocysteine 
residues to form a stable thiol-mercury bond [35].  The first step of this procedure 
is the same as that of the biotin switch.  Following the blocking step, proteins are 
incubated with either the organomercury-conjugated resin (MRC) or a soluble 
phenylmercury-polyethyleneglycol-biotin (mPEGb) compound.  After formation of 
the thiol-mercury bond, a number of options are available.  S-nitrosylated 
proteins can be enriched by either the MRC approach or by avidin-based affinity 
capture (for mPEGb), and eluted using beta-mercaptoethanol to reduce the thiol-
mercury bond.  Eluted proteins are then subjected to 1D gel electrophoresis, in-
gel trypsin digestion, and LC-MS/MS analysis.  In order to identify the specific 
cysteine residues modified by S-nitrosylation, a slightly altered protocol is 
applied.  After incubation of blocked proteins with the phenylmercury-based 
reagents, proteins are then digested with trypsin on-resin or in-solution.  The 
resultant peptides are either eluted with mild performic acid to oxidize the 
cysteine in the thiol-mercury bond to cysteic acid (for the MRC approach), or 
subjected to a combination of avidin-based affinity capture and performic acid 
oxidation.  In both cases, the cysteic acid generated in captured peptides is used 
as the MS signature to identify the cysteine modified by S-nitrosylation.  
Application of these methods yielded 328 endogenous sites of S-nitrosylation in 
192 proteins in the wild-type mouse liver [34].  The method relies on the inclusion 
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of negative controls and the reporting of the percentage of peptides identified as 
false positives (those shared between negative controls and experimental 
samples).   
Advantages of this approach include the fact that it circumvents the 
ascorbate reduction step.  Additionally, it provides an opportunity to pinpoint the 
modified cysteine residue using the MS/MS signature of the cysteic acid (C+48).  
Since both proteins and peptides are identified independently, the peptides can 
be matched to the proteins and thus not rely on a single peptide for protein 
identification, as in previous methods [12, 13]. 
 
2.7   Overview of mass-spectrometry-based methodologies for detection of 
S-nitrosylated proteins 
As with any other PTM-based proteomic studies, there are some potential 
caveats associated with global analyses of in vivo S-nitrosylated proteins.  (1) Up 
to this point, only a few methods afford sensitivity for in vivo detection, and often 
investigators rely on the induction of S-nitrosylation by applying exogenous nitric 
oxide donors or trans-nitrosylating agents to cells and protein preparations.  
Unfortunately, such studies provide only putative sites of modification, not 
necessarily those modified in vivo [36]. (2) Some methods, but not all, do not 
provide the site of modification.  The identification of the site not only provides 
confidence for the correct identification of the protein but also enables follow-up 
studies, such as mutational analysis, to explore biological function.  (3)  Negative 
controls and the reporting of false identification rate (FIR) must be routinely 
evaluated.  (4) We must also consider the possibility that even a method which 
identifies the sites of modification, with appropriate negative controls and low 
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FIR, may still only report a subset of the modified proteins that are either most 
abundant or more stable.  Despite these limitations, it is still worthwhile to pursue 
inquiries into the S-nitrosoproteome, if only to provide more information about the 
structural and functional importance of this modification in vivo. 
 
2.8 Conclusions 
Compared to widespread studies of PTMs such as protein 
phosphorylation, glycosylation, or even acetylation, the field of S-nitrosylation 
represents relatively uncharted territory.  Within the last few years, however, this 
area of research has become quite prominent due to improvements in the 
detection of S-nitrosylated cysteine residues.  By applying mass spectrometry-
based proteomics, a greater appreciation of the biological significance of this 
modification is emerging.  Additional work is needed to improve the sensitivity of 
these methods.  Armed with sensitive and specific techniques, the S-
nitrosoproteome of multiple organs and/or cell types can be investigated.  The 
rich data from such studies can be analyzed in a variety of ways.  Structurally, it 
can reveal significant new insights on elements that guide the selectivity of the 
modification.  Additionally, it can also provide clues to potential biochemical 
reactions that derive the modification as well as explore the relative stability of 
different sites of modification.  Functional analyses can uncover pathways and 
functional clusters of S-nitrosylated proteins, as well as their cellular location(s) 
[37], allowing for development of novel hypotheses that can be tested using more 
targeted approaches.  
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Table 2.1 
Method Principles Comments 
1) Biotin Switch Technique 
(BST): 
The original method and 
several variations 
thereafter:  
-Detergent-free BST 
-SNOSID 
-d-Switch 
-His-Tag Switch 
-Fluorescent Switch/2D-DIGE 
-SNO-RAC 
1) Blockage of free thiols with 
thiosulfonate MMTS 
2) Ascorbate reduction of S-
nitrosocysteine. 
3) Reaction of ascorbate-
generated free cysteine with 
biotin-HPDP (or other thiol-
reactive compounds). 
4) Enrichment of labeled proteins 
or peptides.  
2D-DIGE to assess relative 
changes in S- nitrosylation levels. 
5) Western blot or LC-MS/MS to 
identify protein targets.  
6) Peptide enrichment allows site-
specific identification of modified 
cysteine residues. 
Collectively 135 
endogenously-modified 
protein targets have 
identified. 
82 endogenous sites on 63 
proteins were also identified 
Proteomics applicability. 
Reliance on selective 
reduction of SNO moiety 
prior to labeling, which has 
been discussed previously 
(20-26). 
2) Direct Detection by ESI-
QTOF Mass Spectrometry  
Direct detection of SNO moiety 
on modified proteins. 
Site-specific identification 
Limited to isolated proteins 
or peptides. 
3) Phosphine-based 
derivatization 
Specific reaction of SNO moiety 
on proteins with phosphine-based 
compounds without blocking free 
thiols. 
Direct reaction of phosphine 
compounds with S -
nitrosocysteine provides 
selective one-step labeling 
of modified residues. 
Potential applicability for 
mass-spectrometry-based 
proteomics needs to be 
explored.  
4) Gold Nanoparticles 
(AuNPs) 
1) Blockage of free thiols with 
IAM. 
2) Enrichment of SNO-proteins 
via reaction of S-nitrosocysteine 
with AuNPs. 
3) Trypsin digestion and elution of 
bound peptides. 
4) LC-MS/MS to identify sites of 
modification. 
Site-specific identification.  
AuNP reactivity toward S-
nitrosocysteine and S-
glutathionylated cysteine 
residues prevents absolute 
assignment of correct PTM. 
Applied only to purified 
protein preparations, not 
complex mixtures. 
5) Organomercury-based 
Affinity Enrichment  
1) Blockage of free thiols with 
MMTS. 
2) Reaction with organomercury 
reagents. 
3) LC-MS/MS to identify 
independently protein targets and 
sites of modification. 
Site-specific identification of 
328 endogenous S-
nitrosylated peptides in 192 
proteins in a single 
experiment.  
Reliance on 
organomercury-SNO 
chemistry; requires negative 
controls. 
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3.1 Introduction 
 Nitric oxide (NO) is an important physiological regulator of biological 
function in multiple tissues.  NO-mediated signaling contributes to synaptic 
transmission and cerebrovascular coupling in the CNS (1-4).  The biological 
effects of NO are primarily achieved through two molecular mechanisms: (i) the 
activation of soluble guanylate cyclase and downstream cGMP-dependent 
signaling cascades and (ii) S-nitrosylation, the post-translational modification of 
reduced cysteine residues in proteins to generate S-nitrosocysteine.  Protein S-
nitrosylation has emerged as a vital mediator of protein function and signaling. 
The neuronal isoform of nitric oxide synthase (nNOS) produces NO in the 
brain.  Mice with a genetic deletion of nNOS (nNOS-/-) demonstrate various 
phenotypic insufficiencies (5), including deficits in several forms of memory (6-9).  
Furthermore, these mice have decreased presynaptic/postsynaptic excitability 
(10-11) and synaptic plasticity (12-14), effects that may be due to impaired 
glutamatergic neurotransmission. Additionally, nNOS-/- mice exhibit reduced 
neurodegeneration after cerebral ischemia, which may be because of reduced 
glutamate excitotoxicity (15-16).  Therefore nNOS-derived NO could affect 
synaptic activity by regulating glutamate availability.  Many of the effects of NO 
on neurotransmission occur independently of cGMP activation (17-19), 
suggesting another mechanism for NO-dependent regulation of 
neurotransmission. 
Protein S-nitrosylation is an alternative biochemical and molecular 
pathway by which NO could influence neurotransmission in the CNS (20).  
Selective protein S-nitrosylation has been linked to a few postsynaptic processes 
including the regulation of NMDA receptor and AMPA receptor activity, synaptic 
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targeting of PSD-95, gephyrin clustering at GABAergic synapses, surface 
expression of AMPA receptors, and D-serine production (21-27).  However, the 
biological functions of protein S-nitrosylation in the tripartite glutamatergic 
synapse remain mostly unknown.  Here, we used mass spectrometry (MS)-
based proteomic methodologies to identify protein S-nitrosocysteine residues in 
brain homogenates from wild-type, nNOS-/- and eNOS-/- mice.  When coupled 
with metabolomic profiling, enzyme activity measurements, and site-directed 
mutagenesis, the proteomic data indicates that reversible protein S-nitrosylation 
regulates glutamate uptake, metabolism, conversion to glutamine, and 
glutamatergic transmission.    
 
3.2 Results 
Ontological analysis of brain S-nitrosylated proteins  
Mass spectrometric analysis of endogenous S-nitrosylated proteins using 
organomercury-based enrichment approaches (28-30) unearthed 269 sites in 
136 proteins in wild-type mouse brain, 135 sites in 95 proteins in eNOS-/- brain, 
and 71 sites in 53 proteins in nNOS-/- brain (Fig. 1A and Table 3.1).  The 
reduction in the S-nitrosylation of residues and proteins in nNOS-/- (74%) and 
eNOS-/- mice (50%) implied that both NOS isoforms contributed substantially to 
endogenous protein S-nitrosylation (Fig. 2).  To place these observations in 
biological context, we performed gene ontology analysis.  First we constructed a 
reference mouse brain proteome consisting of 7,025 proteins curated from 
previously published reports (31-34) and our experimental data.  Using this 
reference proteome as a background, we performed computational analysis 
using WebGestalt (35) and identified several molecular pathways and cellular 
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processes in which S-nitrosylated proteins were significantly enriched in the wild-
type brain (Fig. 1B and 3).  The computed ratio of enrichment for the top five 
pathways was similar between wild-type and eNOS-/- brains but was reduced in 
nNOS-/- brains (Fig. 1B).  For example, the molecular processes associated with 
the regulation of neurotransmitter levels showed a 67% reduction in nNOS-/- 
brains, a finding consistent with previous descriptions of synaptic deficits in the 
nNOS-/- mice (6-14).  Within the regulation of neurotransmitter level pathway we 
mapped S-nitrosocysteine residues in four proteins: excitatory amino acid 
transporter 2, glutamate dehydrogenase, mitochondrial aspartate 
aminotransferase, and glutamine synthetase (Fig. 1C).   The first three proteins 
were S-nitrosylated in wild-type and eNOS-/-mice, but not in nNOS-/-mice, 
whereas glutamine synthetase showed reduced S-nitrosylation in nNOS-/- mice 
as compared to wild-type and eNOS-/- mice (Fig. 1D and Table 3.1).  We 
confirmed the mass spectrometric-based identification of these S-nitrosylated 
proteins by Western blotting (Fig. 1D), and quantified the fraction of each protein 
modified by S-nitrosylation in wild-type brain (Fig. 1E).  These four proteins are 
major contributors in the glutamate/glutamine cycle (36-39), the biological 
process responsible for managing the metabolic fate and availability of glutamate 
in the synapse.  Overall, the proteomic and ontological analysis indicates that 
proteins involved in the glutamate/glutamine cycle are selectively S-nitrosylated 
by nNOS, implying a role for nitric oxide in the regulation of glutamate 
metabolism. 
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Figure 3.1. Proteomic Identification of Protein S-Nitrosocysteine residues and Gene Ontology Analysis of 
Modified Proteins in wild-type, eNOS-/-, and nNOS-/- Mouse Brain.  A) Identification of S-nitrosylated proteins and their 
corresponding sites of modification in mouse brain (N = 6 mice per genotype).  B) Gene ontology-based functional 
clustering of S-nitrosylated proteins in each genotype.  The Ratio of Enrichment (R) score is calculated as the ratio of the 
observed number (O) of S-nitrosylated proteins with a specific gene ontology (GO) annotation in the WebGestalt database 
to the number of annotated proteins expected (E) to be in the S-nitrosocysteine proteome.  Only the top five pathways in 
the wild-type mouse with the lowest p-values were considered (p < 0.01).  NT = Neurotransmitter.  C) Schematic of 
glutamate metabolism.  Proteins are denoted by their short protein names, as assigned by Uniprot: GLT1 (excitatory 
amino acid transporter 2), GDH (glutamate dehydrogenase), mAspAT (mitochondrial aspartate aminotransferase), and 
GS (glutamine synthetase).  S-nitrosylated proteins are italicized, with the associated sites of modification indicated.  Gln 
= Glutamine, Glu = Glutamate, Asp = Aspartate, Ala = Alanine, α-KG = α-ketoglutarate, Cys = Cysteine.  D) NOS-based 
dependence of S-nitrosylation of glutamate/glutamine cycle effectors.  Modified proteins (denoted as the “SNO-Fraction”) 
within the aforementioned pathway were confirmed by Western blot against specific targets in all genotypes.  The total 
abundance of the indicated protein targets in 30 µg of total homogenate did not obviously differ between genotypes.  (N = 
2 mice per genotype).  E) Quantification of the relative S-nitrosylated fraction for each glutamate/glutamine cycle protein in 
wild-type mouse brain.  Bars represent mean ± SEM (N = 3 mice). 
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Figure 3.2. Reduction in the enrichment of S-nitrosylated proteins in eNOS-/- and nNOS-/- mice.  Representative 
colloidal blue-stained gel showing the enrichment for S-nitrosylated proteins in forebrains from wild-type (WT), eNOS-/-, 
and nNOS-/- mice.  Proteins were resolved by SDS-PAGE over  a 4-cm distance on the gel, visualized by colloidal blue 
staining and scanned using the Odyssey Infrared Imaging System.  The reduced intensity of protein staining in the lanes 
corresponding to eNOS-/- and nNOS-/- brain homogenates relatively to wild-type homogenate, reflects the lower number of 
S-nitrosylated proteins in the brain of knockouts as compared to wild-type mice.  This experiment was repeated twice with 
similar results (N=2 mice per genotype).  
 
 
Figure 3.3. Additional biological processes and cellular functions identified for S-nitrosylated proteins in the 
mouse brain.  Pathways identified by gene ontology analysis are involved in metabolic functions, including NAD/NADH 
metabolism, glucose metabolism and ATP synthesis/consumption.  All pathways described were among the top ten 
pathways enriched in S-nitrosylated proteins (p < 0.01). 
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Regulation of Glutamate/Glutamine Metabolism by Nitric Oxide 
To study the effects of nNOS-derived NO and protein S-nitrosylation on 
the glutamate/glutamine cycle we quantified the fractional isotopic enrichment of 
glutamate-associated metabolites in acutely-isolated hippocampal slices 
following treatment with [2-15N] L-glutamine (Fig. 4).  Steady-state amounts of 
labeled glutamate-associated metabolites were quantified by HPLC and GS-MS 
approaches (40-41) under stimulatory (Mg2+-free) conditions in wild-type, eNOS-/-
, and nNOS-/- mice.  The three genotypes showed similar total amounts of 
glutamate, glutamine, aspartate, alanine and GABA (Fig. 5A), indicating a lack of 
gross metabolic dysfunction.  However, the ratio of intracellular glutamine to 
glutamate was 30% higher in nNOS-/- mice, reflecting potential perturbations in 
glutamate handling (Fig. 5B).  15N-fractional isotopic enrichment for alanine, 
aspartate, and glutamate ranging between 20-30% was significantly decreased in 
nNOS-/- brain slices relative to the other two genotypes, confirming altered 
glutamate allocation in nNOS-/- mice (Fig. 5C).   
To further explore the influence of nNOS-derived NO on the 
glutamate/glutamine cycle, we performed enzymatic assays for glutamate 
dehydrogenase, mitochondrial aspartate aminotransferase and glutamine 
synthetase in mitochondrial extracts and brain homogenates (Fig. 5D).  The 
activities of glutamate dehydrogenase and mitochondrial aspartate 
aminotransferase were significantly increased in nNOS-/- mitochondrial extracts 
as compared to wild-type and eNOS-/- mice (Fig. 5D).  Trans-illumination of wild-
type mitochondrial extracts with ultraviolet (UV) light, a treatment that effectively 
eliminates NO from S-nitrosocysteine residues (42-43), increased the enzymatic 
activities of glutamate dehydrogenase and mitochondrial aspartate 
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aminotransferase in wild-type extracts similar to that measured in nNOS-/- 
extracts (Fig. 5D).  We used selective inhibitors GTP (for glutamate 
dehydrogenase) and aminooxyacetic acid (for mitochondrial aspartate 
aminotransferase) to validate the specificity of the assays.  Each inhibitor 
resulted in >95% loss of activity (Fig. 5D).  Relative to wild-type homogenate, 
glutamine synthetase activity was decreased slightly in nNOS-/- but not in eNOS-/- 
brain homogenate (Fig. 5D).  UV trans-illumination decreased the activity of GS 
in wild-type homogenate (Fig. 5D).  The difference in the reduction of GS activity 
between nNOS-/- mice and wild-type mice exposed to UV light most likely reflects 
contributions from additional nitric oxide synthase isoforms to the S-nitrosylation 
of GS in vivo (Fig. 1D and Table 3.1).  Exposing wild-type homogenate to the 
glutamine synthetase inhibitor L-methionine sulfoximine (MSO) (44) resulted in a 
>95% loss of activity (Fig. 5D).  Together, metabolomic profiling and enzymatic 
activity assays imply that selective nNOS-dependent S-nitrosylation of key 
proteins in the glutamate/glutamine cycle regulates glutamate metabolism. 
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Figure 3.4. Identification of 15N isotopic label in glutamate-associated metabolites. The 15N isotopic label is 
transferred between metabolites during specific enzymatic reactions, as depicted above.  Enzymes indicated in bold 
denote those identified as being S-nitrosylated. 
67 
 
 
Figure 3.5.  Analysis of the Glutamate/Glutamine Cycle in WT, eNOS-/-, and nNOS-/- Mouse Brain.  A) Glutamate-
associated metabolite quantification.  Total metabolite concentrations were determined by HPLC and normalized to 
protein content (N = 3 mice per genotype).  B) Intracellular glutamine/glutamate ratios.  ** P<0.01 as determined by one-
way ANOVA with Tukey post-hoc analysis (N = 3 mice per genotype).  C) Genotypic differences in steady-state glutamate 
metabolism.  15N-based enrichment of glutamate and its associated derivatives was calculated as a percentage of total 
metabolite content  using GC-MS and corrected for natural 15N abundance (15N+1 MPE: molar percent excess of M+1 
metabolite isotopomer).  * P<0.05 compared to wild-type by one-way ANOVA with Tukey post-hoc analysis between 
genotypes (N = 3 mice per genotype).  D) Enzymatic activity of glutamate/glutamine effectors.  Bars represent mean ± 
SEM (N = 3 mice per genotype), and indicate enzymatic activity relative to that measured in untreated extracts from wild-
type mice.  Activities in untreated wild-type extracts: GS = 1259 ± 94 nmol/mg/hr, GDH = 120 ± 15 nmol/mg/min, mAspAT 
= 238 ± 12 nmol/mg/min.  WT + UV denotes extracts exposed to UV trans-illumination before assessing enzymatic 
activity. WT + Inhibitor denotes extracts pre-treated with specific enzymatic inhibitors (GS = 0.5 mM MSO, GDH = 20 μM 
GTP, mAspAT = 1 mM AOAA).  N.D. Not detectable.  *P<0.05, **P<0.01, ***P<0.001 as compared to wild-type by one-
way ANOVA with Tukey post-hoc analysis. 
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Regulation of intracellular transport of glutamate by the S-Nitrosylation of 
excitatory amino acid transporter 2. 
Excitatory amino acid transporter 2 is the primary transporter responsible 
for glutamate uptake in astrocytes of the cerebral cortex (45).  Genetic deletion of 
the transporter results in lethal epileptic seizures in mice, and eventually leads to 
limited postnatal viability (46-47).  Due to its importance in physiological synaptic 
function (48), as well as its identification in the brain S-nitrosocysteine proteome, 
we explored the functional consequences of excitatory amino acid transporter 2 
S-nitrosylation in mouse brain synaptosomal preparations, as well as in a cell 
model.  We quantified sodium (Na+)-dependent glutamate uptake in freshly 
prepared synaptosomes from wild-type, nNOS-/-, and eNOS-/- forebrain in the 
presence or the absence of the excitatory amino acid transporter 2 inhibitor 
dihydrokainate (DHK) (49).  The resulting difference in uptake activity between 
the two treatments (DHK-sensitive) is the glutamate uptake mediated by GLT1.  
Synaptosomal DHK-sensitive glutamate uptake was increased in nNOS-/-
synaptosomes as compared to wild-type synaptosomes (Fig. 6A).  Elimination of 
NO from S-nitrosocysteine residues by pre-treatment of wild-type synaptosomes 
with copper plus ascorbate (50) increased DHK-sensitive glutamate uptake, 
indicating a functional regulatory role for S-nitrosylation.  On the other hand, 
DHK-insensitive Na+-dependent glutamate was similar in synaptosomes 
prepared from the three genotypes, or in synaptosomes prepared from wild-type 
mice after treatment with copper and ascorbate, suggesting that non-GLT1-
mediated uptake was unaffected by the altered concentrations of NO or the 
elimination of S-nitrosylation (Fig. 7A).  We further explored the functional effect 
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of S-nitrosylation in HEK-293T cells that were transiently transfected with 
plasmids expressing either the wild-type rat transporter or a double point mutant 
(C373S/C562S) of the two in vivo S-nitrosylated cysteine residues.  The cysteine 
residue at position 562 in the rat sequence corresponds to cysteine 561 in the 
mouse sequence, because rat GLT1 is one amino acid longer than the mouse 
protein.  To induce protein S-nitrosylation, we treated cells with a non-
physiological concentration of S-nitrosocysteine, which is taken up through the L-
amino acid transport system.  S-nitrosocysteine is an S-nitrosylating agent that 
can transfer an NO equivalent to reduced cysteine residues in proteins (51).  As 
a control, cells were treated with the same concentration of cysteine.  Treatment 
of cells with S-nitrosocysteine resulted in S-nitrosylation of the wild-type 
transporter (Fig. 6B), which correlated with decreased glutamate uptake (Fig. 
6C).  The C373S/C562S transporter was not S-nitrosylated in S-nitrosocysteine-
treated cells (Fig. 6B), and its activity was similar to that of wild-type transporter 
and was unaffected by S-nitrosocysteine treatment (Fig. 6C).  Mutation of one 
cysteine residue (either 373 or 562) to serine resulted in transporter activity 
sensitive to S-nitrosocysteine treatment, indicating that the modification of both 
cysteine residues is required for S-nitrosylation-mediated inhibition of glutamate 
transport (Fig. 7B).  Relative to L-cysteine treatment, exposure of cells to S-
nitrosocysteine did not alter the protein abundance of the wild-type or the 
C373S/C562S mutant transporter (Fig. 6D-6F), but decreased the surface 
abundance of both transporters by 20-25% (Fig. 6G).  Kinetic analysis of GLT1-
mediated glutamate uptake (Fig. 7C) revealed an 81% decrease in the Km of the 
wild-type transporter after S-nitrosocysteine treatment and an 84% decrease in 
Vmax.  Removal of S-nitrosocysteine from the media led to a gradual decrease in 
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the S-nitrosylation of wild-type GLT1 that correlated with a recovery in glutamate 
uptake activity (Figure 6H-6I).  Overall, these data suggest that specific and 
reversible S-nitrosylation of GLT1 at Cys373 and Cys562 regulates the activity of 
the transporter.   
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Figure 3.6. Regulation of GLT1 Function by S-Nitrosylation.  All results are summarized from three mice per genotype 
(A) or three independent experiments in cells (B-I), and plotted as mean ± SEM.  Cells were treated with L-Cysteine (Cys) 
or S-nitrosocysteine (CysNO).  A) The fraction of total Na+-dependent glutamate uptake that was DHK-sensitive was 
greater in synaptosomes from nNOS-/- mice or synaptosomes pre-treated with copper and ascorbate (WT + Cu/Asc) than 
in untreated wild-type synaptosomes.  Na+-dependent uptake in untreated synaptosomes of the indicated genotype: wild-
type = 0.24 ± 0.03 nmol/mg/min, nNOS-/- = 0.26 ± 0.06 nmol/mg/min, eNOS-/- = 0.25 ± 0.04 nmol/mg/min, and WT + 
Cu/Asc = 0.29 ± 0.03 nmol/mg/min.  *P < 0.05 after one-way ANOVA followed by Dunnett post-hoc analysis. B-C) S-
nitrosylation of wild-type GLT1 in HEK-293T cells following CysNO treatment (B) correlated with decreased glutamate 
uptake (C).  Cys-treated wild-type GLT1 = 0.27 ± 0.03 nmol/mg/min, Cys-treated C373S/C562S GLT1 = 0.26 ± 0.04 
nmol/mg/min.  ****P < 0.0001 after two-way ANOVA followed by Bonferroni post-hoc analysis. D-E) Representative blots 
from cell surface biotinylation assays of cells expressing wild-type GLT1 (D) and C373S/C562S GLT1 (E). L, lysate; I, 
intracellular fraction; C, cell surface fraction. 5 μg of total lysate and equivalent dilutions of the other fractions were used.  
T, D, and M refer to trimeric, dimeric, and monomeric GLT1 respectively.  The intracellular fraction of both forms of GLT1 
was increased after CysNO treatment.  F) Quantification of total GLT1 abundance in cell lysate.  G) Quantification of 
plasma membrane abundance of GLT1 after Cys/CysNO treatment.  *P<0.05, **P<0.01 as determined by ANOVA with 
Bonferroni post hoc analysis.  H-I) S-nitrosylation of wild-type GLT1 was reversible (H), and correlated with a recovery in 
glutamate uptake (I).  Wild-type GLT1 cells were exposed to Cys (CTRL) or CysNO, then to fresh media.  Glutamate 
uptake and S-nitrosylation of GLT1 were assessed between after CysNO exposure.  *P < 0.05 after one-way ANOVA 
followed by Bonferroni post-hoc analysis. 
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Figure 3.7. Characterization of GLT1-independent uptake in synaptosomes and GLT1-dependent uptake in cells. 
(A) DHK-insensitive Na+-dependent glutamate uptake does not differ in brain synaptosomes prepared from the three 
genotypes, or in synaptosomes treated with 50 µM copper plus 500 µM ascorbate, suggesting that non-GLT1-mediated 
uptake is unaffected by the altered concentrations of NO or the elimination of S-nitrosylation (N=3 mice per genotype).  
(B) Glutamate uptake is inhibited by CysNO treatment in cells expressing single-cysteine mutants of GLT1 (C373S or 
C562S).  Cells were treated with 0.4 mM of L-Cysteine (Cys) or 0.4 mM S-nitrosocysteine (CysNO) and GLT1 mediated 
update was assessed in the presence of 5 nM 3H-gluatamate. Cys-treated WT GLT1 = 0.27 ± 0.03 nmol/mg/min, Cys-
treated C373S GLT1 = 0.24 ± 0.04 nmol/mg/min, Cys-treated C562S GLT1 = 0.25 ± 0.02 nmol/mg/min (N=3 independent 
experiments). (C) CysNO treatment of the WT transporter leads to altered kinetic parameters of GLT1-mediated 
glutamate uptake.  A saturation curve of Na+-dependent glutamate uptake was determined for 10-1000 μM glutamate in 
cells ectopically expressing the wild-type GLT1 protein. Kinetic parameters were calculated using non-linear regression 
analysis of GLT1-mediated glutamate uptake and plotted as mean ± SEM (N=3 independent experiments).  Km for 
glutamate for Cys-treated WT GLT1 = 293 ± 27 uM, CysNO-treated WT GLT1 = 55 ± 64 uM.  Vmax for Cys-treated WT 
GLT1 = 11.8 ± 0.4 nmol/mg/min, CysNO-treated WT GLT1 = 1.8 ± 0.5 nmol/mg/min. 
 
Molecular Modeling of the Effects of S-nitrosylation   
We used the crystal structure of mouse mitochondrial aspartate 
aminotransferase (PDB 3PD6), human glutamate dehydrogenase (PDB 1L1F) 
and human glutamine synthetase (PDB 2QC8) as templates and generated 
protein structures with the specific S-nitrosylated cysteine residues.  Electrostatic 
74 
 
potentials and partial atomic charges were calculated for S-nitrosylated and 
unmodified cysteine residues.  All three proteins are large multimeric enzymes in 
which pairs of equivalent modifiable cysteine residues from different monomers 
are arranged with their side chains in an antiparallel fashion across from each 
other.  In mitochondrial aspartate aminotransferase each cysteine residue at 
position 106 between chains A and B and C and D are 26Å apart.  In glutamate 
dehydrogenase, each cysteine residue at position 112 between chains A and E, 
B & E and C & F are 20Å apart, whereas cysteine residues 99 and 183 in GS 
between the side chains are about 23Å apart.  S-nitrosylation of the cysteine 
residue makes the side chain significantly more polar, increasing the dipole 
moment from 1.7 Debye to 5.4 Debye.  This increase in polarity results in an 
augmented electrostatic potential which, because of the antiparallel dipole 
arrangement and the effective propagation of electrostatic potentials inside large 
proteins (52-61), produces a repulsive electrostatic 'wedge' between subunits 
(Fig. 8).  This wedge could drive changes in the quaternary structure and provide 
a plausible allosteric mechanism by which S-nitrosylation of cysteine residues 
distant from substrate and cofactor binding sites modulates enzyme activity. 
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Figure 3.8. S-nitrosylation augments electrostatic potential. The crystal structure of mouse mAspAT (PDB 3PD6), 
human GDH (PDB 1L1F) and human GS (PDB 2QC8) were used as templates and protein structures with the specific S-
nitrosylated cysteine residues were generated.  Electrostatic potentials and partial atomic charges were calculated for S-
nitrosylated (shown as SNC) and unmodified (shown as C) cysteine residues. Potential in GDH produced by unmodified 
Cys112 (A) and S-nitrosyl-Cys112 (B). Potential in mAspAT from Cys106/Cys295 (C) and S-nitrosyl-Cys106/ S-nitrosyl-Cys295 
(D). Potential in GS from Cys99, Cys183, Cys269, and Cys346 (E) and S-nitrosyl-Cys99, S-nitrosyl-Cys183, S-nitrosyl-Cys269, 
and S-nitrosyl-Cys346 (F). Isopotential contours are shown at -1kT/e in red and +1kT/e in blue.  Positions of key cysteine 
residues, S-nitrosyl-cysteine residues, and binding site residues are indicated. 
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3.3 Discussion 
S-nitrosylation of cysteine residues represents an alternative signaling 
mechanism through which nitric oxide can expand the functional diversity and 
biological utility of proteins.  We applied a combination of chemical enrichment 
and mass spectrometric technologies to specifically map endogenous sites of S-
nitrosylation in wild-type, nNOS-/-, and eNOS-/- mouse forebrain.  In wild-type 
brain 45 sites of S-nitrosylation in 44 proteins identified by our method have been 
previously reported with various biochemical and proteomic approaches.  The 
current study contributed 225 additional S-nitrosylation sites as well as 92 
additional protein targets, expanding the known endogenous S-nitrosylated 
proteins in the mouse brain.  As with any enrichment method, the identification of 
the endogenous sites of S-nitrosylation is limited by the relative abundance and 
biological stability of S-nitrosocysteine.  Despite these limitations, interrogation of 
the proteomic data coupled with biochemical approaches provided evidence that 
protein S-nitrosylation participates in the coordination of glutamate metabolism 
and neurotransmission.  Specifically, four proteins that regulate glutamate 
uptake, metabolism and conversion to glutamine are functionally regulated by S-
nitrosylation.   
Glutamate uptake through excitatory amino acid transporter 2, the major 
astrocytic transporter of glutamate in the CNS, was reversibly inhibited by S-
nitrosylation at Cys373 and Cys562.  Irreversible alkylation of Cys373 inhibits 
transporter activity (62), whereas the functional role of Cys562 in the rat or Cys561 
in the mouse has not been studied.  Because permissive mutation of these two 
cysteine residues to serine did not alter excitatory amino acid transporter 2 
activity, these data suggest that both cysteine residues are not critical for function 
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but that posttranslational modifications at these residues are important for 
functional regulation.  We speculate that the transient inhibition of the transporter 
may allow for an extended period of increased glutamate concentration within the 
synaptic cleft, promoting neurotransmission and synaptic strengthening.  The 
absence of nNOS-dependent S-nitrosylation of excitatory amino acid transporter 
2 may prevent nNOS-/- mice from achieving this regulation and thereby contribute 
to their phenotype of dysregulated glutamatergic transmission, synaptic plasticity 
and memory (6-14).   
Metabolic studies have indicated that once in astrocytes, a fraction of 
glutamate (estimates vary from 50-70%) is converted to glutamine by glutamine 
synthetase (63-64).  The remaining glutamate in astrocytes is oxidized by 
glutamate dehydrogenase and mitochondrial aspartate aminotransferase to α-
ketoglutarate, which can then enter the TCA cycle (65-66).  The metabolic 
demands placed on astrocytes and neurons may determine the fraction of 
glutamate that is oxidized in the TCA cycle.  Our data indicate that S-nitrosylation 
inhibited glutamate oxidation by glutamate dehydrogenase and mitochondrial 
aspartate aminotransferase, and promoted conversion to glutamine by glutamine 
synthetase (Fig. 5D).  Moreover, the absence of S-nitrosylation of these enzymes 
in nNOS-/- mice resulted in a higher ratio of glutamine to glutamate, consistent 
with increased glutamate oxidation (Fig. 5B - 5C).  The lower fraction of 
glutamate converted to glutamine may contribute to the phenotype of the nNOS-/- 
mice.  Although there are disagreements on the fraction of the re-cycled 
glutamate that participates in neurotransmission, genetic ablation of enzymes in 
the glutamate/glutamine cycle underscore the importance of maintaining this 
cycle in the CNS (67).  Specifically, glutamine synthetase haploinsufficiency 
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leads to increased seizure susceptibility in vivo (68), with complete deletion of the 
gene associated with decreased cortical glutamine and severely limited postnatal 
viability (69).  Glutamate dehydrogenase deletion in vivo leads to increased 
glutamine concentrations in the brain (70), whereas overexpression of the 
enzyme leads to decreased synaptic plasticity and age-dependent loss of 
synaptic and dendritic architecture (71).  During periods of increased synaptic 
activity, the effect of S-nitrosylation on the reallocation of glutamate from 
oxidation to regeneration of glutamine (and subsequent glutamate) provides an 
explanation for how sustained neurotransmission may be achieved in wild-type 
mice but not in nNOS-/- mice.  The S-nitrosylation induced   alteration in 
glutamate metabolism could also explain why nNOS-/- mice are protected from 
cerebral ischemia (15).  Our data suggests that neurons in the nNOS-/- brain 
would avidly oxidize glutamate and consequently exhibit attenuation of the 
ischemia-induced increase in intra-synaptic glutamate (15-17, 72) while providing 
ATP for metabolic processes.  The partial loss of glutamine synthetase activity in 
nNOS-/- brain would hinder glutamate conversion to glutamine (an important 
mechanism of glutamate disposal) but would also spare limited reserves of ATP 
during an ischemic episode, since the glutamine synthetase pathway normally 
consumes considerable energy (73).  Collectively, S-nitrosylation of these 
proteins may provide a regulatory switch between glutamate oxidation and 
glutamine generation to support synaptic maintenance and glutamatergic 
neurotransmission.   
Finally, it is interesting to note that of the 136 proteins identified as targets 
of S-nitrosylation in the wild-type mouse brain, 23 have been identified as part of 
macromolecular complexes implicated in glutamate metabolism at synapses 
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(74).  The association of glutamate uptake and mitochondrial mobility (75), the 
functional interaction between glutamate dehydrogenase-mediated glutamate 
oxidation and excitatory amino acid transporter 2-mediated glutamate uptake 
(76), and the data presented in figures 2 and 3 indicate that selective protein S-
nitrosylation may function as a synapse-specific gatekeeper of glutamate fate 
during neurotransmission. 
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Table 3.1: S-Nitrosocysteine Sites Identified in wild-type, eNOS -/-, and  
nNOS -/- Mouse Brain 
Protein name 
Uniprot 
ID 
Peptide sequence WT 
eNOS 
-/- 
nNOS  
-/- 
10-formyltetrahydrofolate 
dehydrogenase 
Q8R0Y6 AVQMGMSSVFFNKGENC707IAAGR X 
  
14-3-3 protein theta P68254 YLAEVAC134GDDRK X 
  
2',3'-cyclic-nucleotide 3'-
phosphodiesterase 
P16330 
LDEDLAGYC111RR X 
 
X 
LELVSYFGKRPPGVLHC251TTK X 
 
X 
2-oxoglutarate 
dehydrogenase E1 
component, mitochondrial 
Q60597 
TKAEQFYC395GDTEGKK X 
  
SMTC604PSTGLEEDVLFHIGK X X 
 
NTFHKDVVVDLVC497YRR X 
  
4-aminobutyrate 
aminotransferase, 
mitochondrial* 
P61922 
TMGC224LATTHSK X 
  
C269LEEVEDLIVKYR# X X 
 
NKGVVLGGC467GDK X 
 
X 
Acetyl-CoA 
acetyltransferase, 
mitochondrial 
Q8QZT1 IHMGNC193AENTAK X X X 
Aconitate hydratase, 
mitochondrial 
Q99KI0 
VAVPSTIHC126DHLIEAQVGGEK X X 
 
C410KSQFTITPGSEQIR X X X 
C592TTDHISAAGPWLK X 
  
Actin, cytoplasmic 1* P60710 
C285DVDIRKDLYANTVLSGGTTMYPGI
ADR 
X X 
 
Actin-related protein 10 Q9QZB7 C27GFAGETGPR 
 
X 
 
ADP/ATP translocase 1 P48962 EFNGLGDC160LTK X 
  
AP-1 complex subunit 
beta-1 
O35643 AIGRC380AIKVEQSAER X X 
 
AP-2 complex subunit 
alpha-1 
P17426 AC331NQLGQFLQHR X 
  
AP-2 complex subunit 
beta 
Q9DBG3 
C129LKDEDPYVRK X 
  
C380AIKVEQSAER X 
  
AP-2 complex subunit mu P84091 
SGKQSIAIDDC246TFHQC251VR X 
  
YIGRSGIYETRC435 X 
  
Aspartate 
aminotransferase, 
cytoplasmic 
P05201 IANDNSLNHEYLPILGLAEFRSC83ASR X 
  
Aspartate 
aminotransferase, 
mitochondrial* 
P05202 
NLDKEYLPIGGLAEFC106K# X 
  
VGAFTVVC295K# X 
  
ATP synthase subunit 
alpha, mitochondrial 
Q03265 LYC244IYVAIGQKR X 
  
ATP synthase subunit 
gamma, mitochondrial 
Q91VR2 HLIIGVSSDRGLC103GAIHSSVAK X X 
 
ATP-citrate synthase* Q91V92 GVTIIGPATVGGIKPGC623FK X 
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Calcium/calmodulin-
dependent protein kinase 
type II alpha chain 
P11798 
C30VKVLAGQEYAAK X X 
 
QETVDC290LKKFNAR X 
  
Calcium/calmodulin-
dependent protein kinase 
type II beta chain* 
P28652 
C31VKLC35TGHEYAAK X X X 
STVASMMHRQETVEC290LKK# X X 
 
Citrate synthase, 
mitochondrial* 
Q9CZU6 
GYSIPEC101QKMLPK# X 
 
X 
LPC211VAAK X 
 
X 
YSC359QREFALK X X 
 
Clathrin heavy chain 1* Q68FD5 
HSSLAGC151QIINYR X 
 
X 
AHIAQLC617EK X 
  
IHEGC870EEPATHNALAK X X 
 
YC909EKRDPHLAC918VAYER X X 
 
C1205YDEKMYDAAK X X 
 
CLIP-associating protein 2 Q8BRT1 IPRPSVSQGC534SR 
 
X 
 
Creatine kinase B-type 
 
Q04447 
 
SIRGFC141LPPHC146SR X X X 
FC254TGLTQIETLFK X X 
 
LGYILTC282PSNLGTGLR X X X 
Creatine kinase, 
ubiquitous mitochondrial* 
P30275 
KHNNC63MASHLTPAVYAR X X X 
LGYILTC317PSNLGTGLR X X X 
Cullin-associated NEDD8-
dissociated protein 1 
Q6ZQ38 LDRLVEPLRATC1153TTK X 
  
Cysteine and glycine-rich 
protein 1 
P97315 
TVYFAEEVQC25EGNSFHK X 
  
NLDSTTVAVHGEEIYC58KSC61YGKK X 
  
C122SQAVYAAEK X X 
 
Cysteine-rich protein 2 Q9DCT8 C8DKTVYFAEK X X X 
Cytochrome b-c1 complex 
subunit 6, mitochondrial* 
P99028 
ERLELC51DNRVSSR X X 
 
DHC79VAHKLFK X 
  
Cytochrome c oxidase 
subunit 5B, mitochondrial* 
P19536 C112PNC115GTHYKLVPHQMAH# X X X 
Cytochrome c, somatic P62897 IFVQKC15AQCHTVEKGGK X 
  
Cytochrome c1, heme 
protein, mitochondrial 
Q9D0M3 
 
ARHGGEDYVFSLLTGYC219EPPTGVS
LR 
 
X   
Cytosolic 5'-nucleotidase 
III-like protein 
Q3UFY7 
C48PSSHNILDNSK X 
  
AHSLLC106QQR X 
  
D-3-phosphoglycerate 
dehydrogenase 
Q61753 ALVDHENVISC281PHLGASTK X X X 
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D-beta-hydroxybutyrate 
dehydrogenase, 
mitochondrial 
Q80XN0 
GFLVFAGC86LMK X 
  
SPYC209ITK X 
  
TIQLNVC115NSEEVEKAVETIR X 
  
D-dopachrome 
decarboxylase 
O35215 LC24AATATILDKPEDR X 
  
Destrin Q9R0P5 
C23STPEEIK X X 
 
AVIFC39LSADKK X X 
 
Dihydrolipoyl 
dehydrogenase, 
mitochondrial* 
O08749 VC484HAHPTLSEAFR X X 
 
Dihydropyrimidinase-
related protein 1 
P97427 
SHKSTVEYNIFEGMEC439HGSPLVVIS
QGK 
X 
  
Dihydropyrimidinase-
related protein 2* 
O08553 
SITIANQTNC248PLYVTK# X X 
 
THNSALEYNIFEGMEC439R# X X 
 
GVPRGLYDGPVC504EVSVTPK# X X 
 
Dihydropyrimidinase-
related protein 3 
Q62188 FIPC471SPFSDYVYKR X X 
 
Dihydropyrimidinase-
related protein 5 
Q9EQF6 
DSELYQVFHAC181R X X 
 
C432HGVPLVTISR X X 
 
DmX-like protein 2* Q8BPN8 
HGNIQVSC62VEC65SNQHGR X 
  
C1373IAGEVAIVRDPDAGEGTKR X 
  
VINLSQYGPAC1504FGQEHAR# X 
  
LHTC1577LLTSLPPLYR X 
  
SC1832NPVVFSFYNYLR X 
  
VGC1896PVLALEVLSKIPK X 
  
Dpys protein (Fragment) Q8K0X3 C433HGVPLVTISR 
  
X 
Electron transfer 
flavoprotein-ubiquinone 
oxidoreductase, 
mitochondrial 
Q921G7 
VTVFAEGC247HGHLAK X 
  
LQINAQNC585VHC588K X 
  
Elongation factor Tu, 
mitochondrial 
Q8BFR5 KGDEC290ELLGHNK X 
  
ES1 protein homolog, 
mitochondrial 
Q9D172 
KPIGLC174C175IAPVLAAK X X 
 
HC219VKGVTEAHVDQK X X 
 
NKVVTTPAFMC242ETALHHIHDGIGAM
VK 
X X 
 
Excitatory amino acid 
transporter 2 
P43006 
C373LEDNLGIDKR X X 
 
SADC561SVEEEPWKR X X 
 
Fascin (Fragment) 
D3YWW
3 
LINRPIIVFRGEHGFIGC397R 
  
X 
Fatty acid synthase* P19096 
C1084LGITVSGGIHISR X 
  
C1464ILLSNLSNTSHAPK X 
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Fructose-bisphosphate 
aldolase A 
P05064 
QLLLTADDRVNPC73IGGVILFHETLYQ
K 
X 
 
X 
C150VLKIGEHTPSALAIMENANVLAR X 
  
YASIC178QQNGIVPIVEPEILPDGDHDL
KR 
X 
  
C202QYVTEK X 
 
X 
ALANSLAC339QGK X X  
Fructose-bisphosphate 
aldolase C 
P05063 
KC73IGGVIFFHETLYQKDDNGVPFVR X 
  
C150VLKISDRTPSALAILENANVLAR X 
  
YASIC178QQNGIVPIVEPEILPDGDHDL
KR 
X 
  
C202QYVTEKVLAAVYK X 
  
Fructose-bisphosphate 
aldolase 
Q9CPQ9 
QLLLTADDRVNPC73IGGVILFHETLYE
K 
X X X 
C202QYVTEKVLAAVYK X X X 
ALANSLAC339QGK X X X 
Galectin-related protein A Q8VED9 LIVPFC41GHIK 
 
X 
 
Glutamate decarboxylase 
1 
P48318 
LGLKIC47GFLQR X X 
 
QSSKNLLSC78ENSDQGAR X X 
 
Glutamate dehydrogenase 
1, mitochondrial 
P26443 IIKPC112NHVLSLSFPIR X X 
 
Glutamine synthetase* P15105 
LVLC99EVFK X 
 
X 
AC183LYAGVK X X 
 
C269IEEAIDKLSK# X X 
 
RPSANC346DPYAVTEAIVR# X X 
 
Glyceraldehyde-3-
phosphate 
dehydrogenase* 
P16858 
IVSNASC150TTNC154LAPLAK# X X 
 
VPTPNVSVVDLTC245R X X 
 
Glycerol-3-phosphate 
dehydrogenase, 
mitochondrial 
Q64521 
C270KDVLTGQEFDVR X X 
 
C285VINASGPFTDSVR X X 
 
Glycogen phosphorylase, 
brain form* 
Q8CI94 
FGC319RDPVR X 
 
X 
QLLNC581LHIITLYNR X 
 
X 
Guanine nucleotide-
binding protein G(i), 
alpha-2 subunit 
P08752 EIYTHFTC326ATDTK X 
  
Guanine nucleotide-
binding protein 
G(I)/G(S)/G(T) subunit 
beta-1* 
P62874 
KAC25ADATLSQITNNIDPVGR# X X 
 
ELAGHTGYLSC148C149R# X X X 
LFVSGAC204DASAK# X X 
 
ADQELMTYSHDNIIC271GITSVSFSK X X 
 
Heat shock protein 105 
kDa 
Q61699 
FIC659EQEHEK X X 
 
VKELNNVC797EPVVTQPKPK X X 
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Hexokinase-1* P17710 
ATDC684VGHDVATLLR X 
 
X 
KLPVGFTFSFPC214R X 
 
X 
Histidine triad nucleotide-
binding protein 1 
P70349 C84AADLGLKR X X 
 
Huntingtin P42859 
LRGGGGNVTLGEC1706SEGK X 
  
C1940ENLSTPTTLKK X 
  
Hypoxanthine-guanine 
phosphoribosyltransferase 
P00493 DLNHVC206VISETGK X 
  
Inositol monophosphatase O55023 LC183SIPIHGIR X X 
 
Inositol-3-phosphate 
synthase 1 
Q9JHU9 
 
SSVVDDMVHSNHVLYAPGERPDHC38
0VVIK 
 
X 
 
X 
  
Isocitrate dehydrogenase 
[NAD] subunit alpha, 
mitocondrial* 
Q9D6R2 
KTFDLYANVRPC49VSIEGYK X 
  
DLGGNAKC351SDFTEEIC359RR# X 
  
Isocitrate dehydrogenase 
[NAD] subunit gamma, 
mitochondrial 
P70404 
TSLDLYANVIHC148K X X X 
NIANPTATLLASC333MMLDHLK X X X 
Isoform 11 of Myelin basic 
protein 
P04370-
11 
SRPGLC79HMYKDSHTR 
 
X 
 
Isoform M1 of Pyruvate 
kinase isozymes M1/M2 
P52480 
NTGIIC49TIGPASR X 
  
AGKPVIC326ATQMLESMIK X 
  
C423LAAALIVLTESGRSAHQVAR X 
  
L-asparaginase Q8C0M9 
C114IANPVKLAR X X 
 
TPHC132FLTGHGAEK X X 
 
LIM and SH3 domain 
protein 1 
Q61792 KPYC53NAHYPK X X X 
L-lactate dehydrogenase 
A chain 
P06151 
IVSSKDYC84VTANSK X X 
 
VIGSGC163NLDSAR X X 
 
L-lactate dehydrogenase 
B chain 
P16125 HRVIGSGC164NLDSAR X X 
 
Long-chain-fatty-acid--
CoA ligase 6 
Q91WC3 VIQSVVYC336HGGR X X 
 
Malate dehydrogenase, 
cytoplasmic* 
P14152 
VIVVGNPANTNC137LTASK# X 
 
X 
SAPSIPKENFSC154LTR# X X X 
Malate dehydrogenase, 
mitochondrial 
P08249 
VNVPVIGGHAGKTIIPLISQC212TPK X X X 
ETEC285TYFSTPLLLGKK X 
  
Microtubule-associated 
protein 1A* 
Q9QYR6 
SIEEAC160LTLQHLNR X X 
 
SAPC2165GSLAFSGDR# X X 
 
Microtubule-associated 
protein 1B 
P14873 
SALRDAYC1224SEEKELK X X 
 
TIKSPC1913DSGYSYETIEK X 
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Microtubule-associated 
protein 2 
P20357 
YTRPTHLSC1506VK X 
  
KIDLSHVTSKC1709GSLK X 
  
Microtubule-associated 
protein RP/EB family 
member 3 
Q6PER3 LSNVAPPC182ILRK X 
 
X 
Microtubule-associated 
protein tau 
P10637 C614GSLGNIHHKPGGGQVEVK X X 
 
Mitochondrial carrier 
homolog 2 
Q791V5 
QVC49QLPGLFC56YAQHIASIDGRR X X 
 
LC79SGVLGTVVHGK X X X 
Mitochondrial glutamate 
carrier 1 
Q9D6M3 GVNEDTYSGFLDC271ARK X 
  
Myelin proteolipid protein* P60202 
TTIC109GKGLSATVTGGQK X X X 
TSASIGSLC201ADAR# X X X 
NAD-dependent protein 
deacetylase sirtuin-2 
Q8VDQ8 C164YTQNIDTLER X 
 
X 
NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 6, mitochondrial 
P52503 
IIAC79DGGGGALGHPK X X X 
TGTC104GYCGLQFKQHHH X X 
 
Non-POU domain-
containing octamer-
binding protein 
Q99K48 FAC147HSASLTVR X X X 
Peptidyl-prolyl cis-trans 
isomerase A* 
P17742 
IIPGFMC62QGGDFTR X X X 
HTGPGILSMANAGPNTNGSQFFIC115T
AK 
X 
  
KITISDC161GQL# X X X 
Peroxiredoxin-5, 
mitochondrial* 
P99029 KGVLFGVPGAFTPGC96SK X 
  
Phytanoyl-CoA 
hydroxylase-interacting-
like protein 
Q8BGT8 KDPSC321KTC324NISVGR X X 
 
Plexin-A1 P70206 
IQSC374YRGEGK X 
 
X 
GYEC742LFHIPGSPAR X X X 
C1011LTPPGHTPGSAPIVININR X X X 
Profilin-1 P62962 C128YEMASHLR X X 
 
Protein DJ-1 Q99LX0 
VTVAGLAGKDPVQC46SR X X 
 
KGLIAAIC106AGPTALLAHEVGFGC121K X X 
 
Protein kinase C and 
casein kinase substrate in 
neurons protein 1 
Q61644 AYHLAC161KEER X X 
 
Protein kinase C beta 
type* 
P68404 
C132DTC135MMNVHKR X X 
 
C143VMNVPSLC151GTDHTERR X X 
 
Protein phosphatase 1 
regulatory subunit 1B 
Q60829 RPNPC72AYTPPSLK X 
  
Putative uncharacterized 
protein 
Q3ULN6 SVSC218LKPVPIVGTK 
  
X 
Pyridoxal kinase Q8K183 C273AKAEAGEGQKPSPAQLELR X X 
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Pyruvate dehydrogenase 
E1 component subunit 
alpha, somatic form, 
mitochondrial*  
P35486 
C41DLHRLEEGPPVTTVLTR X X X 
EATKFAAAYC273R X X X 
Pyruvate dehydrogenase 
E1 component subunit 
beta, mitochondrial 
Q9D051 
QGTHITVVAHSRPVGHC249LEAAAVL
SK 
X 
  
Pyruvate kinase isozymes 
M1/M2 
P52480 
NTGIIC49TIGPASR X X X 
AGKPVIC326ATQMLESMIK 
 
X 
 
X 
  
Rab GDP dissociation 
inhibitor alpha 
P50396 
IIC302ILSHPIK X X X 
KSDIYVC335MISFAHNVAAQGK X X X 
Rab GDP dissociation 
inhibitor beta 
Q61598 
VGQVIRVIC302ILSHPIK X X 
 
KSDIYVC335MISFAHNVAAQGK X X X 
Ras-related C3 botulinum 
toxin substrate 1 
P63001 
HHC105PNTPIILVGTK X X X 
AVLC178PPPVKK X X X 
Ras-related protein Rab-
14 
Q91V41 
SC26LLHQFTEK X X 
 
FMADC40PHTIGVEFGTR X X 
 
Sarcoplasmic/endoplasmi
c reticulum calcium 
ATPase 2 
O55143 
SMSVYC498TPNKPSR X 
  
GAPEGVIDRC524THIR X 
  
C560LALATHDNPLKR X 
  
NYLEQPGKEC998VQPATK X X X 
Secernin-1 Q9CZC8 
C186IC188NHLSLATKLDEEHPELR X X X 
SSPC290IHYFTGTPDPSR X X X 
Septin-5 Q9Z2Q6 DVTC300DVHYENYR X X X 
Serum albumin P07724 LQTC302C303DKPLLKK X 
  
S-methyl-5'-thioadenosine 
phosphorylase 
Q9CQ65 
TSLRPQTFYDGSHC130SAR X 
  
C163HSKGTIVTIEGPR X 
  
Sodium- and chloride-
dependent GABA 
transporter 3 
P31650 TVTVNDC607EAKVKGDGTISAITEK X 
  
Sodium/potassium-
transporting ATPase 
subunit alpha-1 
Q8VDN2 
C518SSILLHGK X X X 
AAVPDAVGKC606R X 
  
DAKAC663VVHGSDLK X 
  
LIIVEGC705QRQGAIVAVTGDGVNDSP
ALKK 
X 
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Sodium/potassium-
transporting ATPase 
subunit alpha-2* 
Q6PIE5 
IISSHGC209KVDNSSLTGESEPQTR X X 
 
ILDRC515STILVQGK X X 
 
VLGFC553QLNLPSGKFPR X 
 
X 
AAVPDAVGKC603R X 
  
LIIVEGC702QRQGAIVAVTGDGVNDSP
ALKK# 
X 
  
Sodium/potassium-
transporting ATPase 
subunit alpha-3* 
Q6PIC6 
YNTDC49VQGLTHSKAQEILAR# X X X 
IISAHGC201KVDNSSLTGESEPQTR# X X X 
SPDC221THDNPLETR X X 
 
DVAGDASESALLKC449IELSSGSVK# X 
  
ILDRC508ATILLQGK# X 
  
VLGFC546HYYLPEEQFPK X 
  
AAVPDAVGKC596R X 
 
X 
AC653VIHGTDLK# X 
  
LIIVEGC695QRQGAIVAVTGDGVNDSP
ALKK# 
X 
  
Sodium/potassium-
transporting ATPase 
subunit beta-1* 
P14094 YNPNVLPVQC214TGKR# X 
  
Succinate dehydrogenase 
[ubiquinone] flavoprotein 
subunit, mitochondrial 
Q8K2B3 
TYFSC266TSAHTSTGDGTAMVTR X 
  
AC467ALSIAESC475RPGDKVPSIK X X X 
Superoxide dismutase 
[Cu-Zn]* 
P08228 AVC7VLKGDGPVQGTIHFEQK# X X 
 
Synaptophysin* Q62277 LHQVYFDAPSC87VK# X 
  
Syntaxin-binding protein 1 O08599 
AAHVFFTDSC110PDALFNELVK X X 
 
LAEQIATLC180ATLKEYPAVR X X 
 
TAR DNA-binding protein 
43 
E9Q830 YRNPVSQC50MR 
 
X 
 
Transketolase P40142 DRTVPFC386STFAAFFTR X 
 
X 
Tubulin alpha-1A chain* P68369 
AYHEQLSVAEITNAC295FEPANQMVK
# 
X 
  
YMAC315C316LLYRGDVVPK X X 
 
TIQFVDWC347PTGFK X 
  
Tubulin alpha-1B chain P05213 C305DPRHGKYMAC315C316LLYR X X X 
Tubulin alpha-4A chain* P68368 
C305DPRHGKYMAC315C316LLYR X X 
 
SIQFVDWC347PTGFK# X 
 
X 
Tubulin beta-2A chain Q7TMM9 
MREIVHIQAGQC12GNQIGAK X 
  
NMMAAC303DPRHGRYLTVAAIFR X 
  
TAVC354DIPPRGLK X 
  
Tubulin beta-2B chain* Q9CWF2 
EIVHIQAGQC12GNQIGAK X 
 
X 
NMMAAC303DPRHGR X 
 
X 
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Tubulin beta-2C chain* P68372 
EIVHIQAGQC12GNQIGAK# X 
  
TLKLTTPTYGDLNHLVSATMSGVTTC2
39LR 
X 
  
NMMAAC303DPRHGRYLTVAAVFR X X X 
TAVC354DIPPRGLK X 
  
Tubulin beta-3 chain Q9ERD7 
MREIVHIQAGQC12GNQIGAK X 
  
VAVC354DIPPRGLK X 
  
Tubulin beta-4 chain* Q9D6F9 EIVHLQAGQC12GNQIGAK# X 
  
Tubulin beta-5 chain P99024 
MREIVHIQAGQC12GNQIGAK X 
  
NMMAAC303DPRHGRYLTVAAVFR X 
  
TAVC354DIPPRGLK X 
  
Tubulin polymerization-
promoting protein 
Q7TQD2 LC79KDC82HVIDGK X X 
 
Ubiquitin carboxyl-terminal 
hydrolase isozyme L1* 
Q9R0P9 
NEAIQAAHDSVAQEGQC152R X 
  
FSAVALC220K X X X 
Ubiquitin thioesterase 
OTUB1 
Q7TQI3 TRPDGNC91FYR X X 
 
Ubiquitin-conjugating 
enzyme E2 O 
Q6ZPJ3 
LGC336FDHAQR X 
  
C348LYVFPAKVEPAK X X 
 
Ubiquitin-like modifier-
activating enzyme 1 
Q02053 
YSRPAQLHIGFQALHQFC340ALHNQP
PRPR 
X 
  
C588VYYRKPLLESGTLGTK X X 
 
Uncharacterized protein E9QM90 
LSPAFHQALLSFC497R X 
  
C526LPHIVPNVLLAK X 
  
Vesicle-fusing ATPase* P46460 
C11PTDELSLSNC21AVVNEKDFQSGQ
HVMVR 
X 
  
THPSVVPGC59IAFSLPQRK X X 
 
GILLYGPPGC264GK X 
 
X 
Voltage-dependent anion-
selective channel protein 
3* 
Q60931 
YKVC65NYGLTFTQK# X X 
 
YKLDC229RTSLSAK X 
  
V-type proton ATPase 
subunit B, brain isoform 
P62814 
KTSC112EFTGDILR X 
  
GQKIPIFSAAGLPHNEIAAQIC207R X 
  
Zinc transporter ZIP6 Q8C145 
KAFC153PDLDSDNSGKNPR X X 
 
AC312LIHTASEK X X 
 
X denotes identification of peptide in a given genotype. The peptides corresponding to wild-type 
mice have been identified in at least three biological replicates.  
* denotes proteins identified in previously published studies as endogenously S-nitrosylated in 
mouse brain 
# denotes peptides identified in previously published studies as endogenously S-nitrosylated in 
mouse brain 
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3.4 Materials and Methods 
Chemicals and Reagents 
Chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless 
otherwise indicated.  Rabbit polyclonal antibody against GLT1 was a gift from Dr. 
Jeffrey Rothstein (Johns Hopkins University School of Medicine, Baltimore, MD).  
Goat polyclonal antibodies against mAspAT and GDH were purchased from 
Abcam (Cambridge, MA).  Mouse monoclonal antibody against GS was 
purchased from Millipore (Bedford, MA).  L-[3,4-3H] glutamic acid was purchased 
from Perkin-Elmer (Waltham, MA).  Affigel-10 was purchased from Bio-Rad 
(Hercules, CA). EZLink Sulfo-NHS-Biotin and UltraLink monomeric avidin beads 
were purchased from Pierce (Rockford, IL). 
Animals 
All procedures were performed in strict accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and were 
approved by the Children’s Hospital of Philadelphia Animal Care and Use 
Committee.  Male mice between 10-12 weeks old were used for proteomic 
studies, enzymatic assays and synaptosomal uptake, while those between 8-10 
weeks old were used for 15N stable isotopic profiling.  Wild-type C57BL/6J 
(#000664), Nos1tm1Unc C57BL/6J (nNOS–/–: #002986), and Nos3tm1Unc C57BL/6J 
(eNOS-/-: #002684) mice were obtained from Jackson Laboratories (Bar Harbor, 
ME).  For experiments except those involving isotopic profiling, mice were 
anesthetized by CO2 and perfused through the left ventricle with ice-cold PBS.  
Intact organs were collected, immediately frozen in liquid nitrogen, and stored at -
80 °C until use.  
Identification of Protein S-Nitrosocysteine Sites 
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A detailed experimental procedure for the preparation and activation of 
columns, as well homogenate preparation for reaction with organic mercury 
resin, has been previously published (30).  Six biological replicates from each 
genotype were analyzed. Each sample had a corresponding UV-pretreated 
negative control analyzed under identical conditions. The number of peptides 
identified in both untreated and UV-pretreated homogenates was used to 
calculate the false identification rate (FIR).  The FIR was calculated 
independently for each biological replicate and the average value is reported.  
Overall, the FIR across the six biological replicates was 5.2 ± 0.7 %, which is 
within the range of FIR reported for site specific identification of other post-
translational modifications using enrichment approaches (77-78).  Columns were 
initially washed with 50 bed volumes of 50 mM Tris-HCl, pH 7.4, containing 0.3 M 
NaCl, 0.5% SDS, followed by 50 bed volumes of the same buffer containing 
0.05% SDS.  Columns were then washed with 50 bed volumes of 50 mM Tris-
HCl pH 7.4, containing 0.3 M NaCl, 1% Triton X-100, 1M Urea.  This was 
followed by 50 bed volumes of the same buffer containing 0.1% Triton X-100, 0.1 
M urea.  Finally, columns were washed with 200 bed volumes of water before 
proteins were eluted with 10 mL of 50 mM β-mercaptoethanol in water.  Samples 
were concentrated and resolved by one-dimensional SDS-PAGE, followed by 
either western blot analysis or in-gel trypsinization and subsequent LC-MS/MS 
analysis (28-30, 79).   
 For quantification of S-nitrosylated GLT1, GDH, mAspAT, and GS from 
wild-type mouse brain, the same protein capture protocol described above was 
followed.  The eluted bound proteins, representing the S-nitrosylated fraction, 30 
µg of input homogenate (total protein) and different dilutions of recombinant 
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standard proteins were resolved by one-dimensional SDS-PAGE and transferred 
to Immobilon-FL PVDF membranes (Millipore, Bedford, MA).  After probing with 
appropriate antibodies, blots were scanned by the Odyssey Infrared Imaging 
System (LI-COR, Lincoln, NE).   
To identify sites of S-nitrosocysteines, columns were washed with 10 bed 
volumes of 0.1 M ammonium bicarbonate after the final wash with water in the 
previously described method.  Bound proteins were subjected to digestion by the 
addition of 1 μg/mL of trypsin gold (Promega, Madison, WI) in one bed volume of 
0.1 M ammonium in the dark for 16 hours at room temperature. The resin was 
next washed with 40 bed volumes of 1 M ammonium bicarbonate, pH 7.4, 
containing 300 mM NaCl, followed by 40 volumes of the same buffer without 
NaCl.  Columns were then washed with 40 volumes of 0.1 M ammonium 
bicarbonate followed by 200 volumes of deionized water.  Performic acid was 
synthesized by reacting 1% formic acid and 0.5% hydrogen peroxide for at least 
60 minutes at room temperature (with rocking) in a glass vial shielded from light.  
To elute bound peptides, the resin was incubated with one bed volume of 
performic acid in water for 30 minutes at room temperature (28-30).  Eluted 
peptides were recovered by washing the resin with one bed volume of deionized 
water.  Eluates were stored at -80 °C overnight followed by lyophilization and re-
suspension into 300 μL of 0.1% formic acid. Peptide suspensions were 
transferred to low retention tubes (Axygen, Union City, CA) and the volume was 
reduced to 30 μL by speed vacuum. Twenty μL of peptide suspension was 
transferred to an HPLC vial and submitted for LC-MS/MS analysis.  The details 
for MS/MS analysis have been provided previously (28-30, 79).  Post-MS 
analysis to generate the S-nitrosocysteine proteomes (Table S1) was performed 
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as described previously (28-30). The peptides that are reported for the wild-type 
mice had been identified in at least three biological replicates.  
Gene Ontology Analysis 
Proteins in supplemental table S1 were mapped to UniprotIDs and only 
reviewed, non-fragment proteins were retained in the final proteome.  A mouse 
brain reference brain proteome consisting of 7025 proteins was generated from 
the literature (31-34) and our experimental data.  For gene ontology (GO) 
analysis, the Ratio of Enrichment (R) score was calculated by WebGestalt (35) 
as the ratio (O/E) of the observed number (O) of proteins with a specific GO 
annotation in the S-nitrosocysteine proteome vs. the number of annotated 
proteins expected (E) to be in the S-nitrosocysteine proteome.  E is derived from 
the number of proteins annotated as part of a specific molecular pathway in the 
whole brain proteome normalized to the number of total proteins in the whole 
brain protein proteome (and multiplied by the total number of S-nitrosylated 
proteins).  Significant enrichment was evaluated at an adjusted cutoff of 0.01, 
with the top ten enriched pathways considered for further analysis. 
Glutamate/Glutamine Metabolism Studies 
For isotopic profiling studies, three mice per genotype were analyzed. 
Each day samples from one mouse per genotype were prepared and analyzed.  
Animals were anesthetized with isoflurane and decapitated.  The brain was then 
rapidly removed and coronal hippocampal slices (400 μm) cut with a vibratome 
(Vibratome 1000 Plus, Vibratome, St. Louis, MO) in an ice-cold artificial 
cerebrospinal fluid solution (ACSF) of the following composition: 202 mM 
sucrose, 3 mM KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 10 mM glucose, 1 mM 
MgCl2, 2 mM CaCl2, pH 7.2–7.4 (when saturated with 95% O2-5% CO2).  Slices 
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were then equilibrated for 2 hours at 34°C in ACSF containing 130 mM NaCl 
instead of sucrose.  Following equilibration, hippocampal slices were transferred 
into cell culture inserts and incubated in a 24-well plate for 45 minutes at 34°C in 
1 mL depolarizing artificial cerebrospinal fluid (dACSF) containing the following: 
130 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 10 mM glucose, 
2 mM CaCl2, 1 mM [2-15N] L-glutamine, and 0.3 mM NH4Cl.  Medium was then 
collected from each sample and frozen at -80°C, and slices were washed with 2 
mL chilled D-PBS.  Slices were homogenized in 4% perchloric acid and 
subjected to two freeze/thaw cycles, with a subsequent centrifugation step at 
10000 x g for 15 minutes.  Supernatant was collected from each slice, which 
contained the metabolites of interest, and protein pellets were separately 
resuspended in 1 M NaOH.  Protein content per slice was determined using the 
Bio-Rad Protein Assay (Bio-Rad, Hercules, CA).  Supernatant from each sample 
was neutralized with KOH and used for metabolite determination and 
measurement of 15N enrichment by GC-MS (40-41). 
Enzymatic Assays 
For enzymatic activities three mice per genotype were analyzed.  Each 
day, three mice (one mouse per genotype) were analyzed. Enzymatic activities 
were quantified in triplicates with technical reproducibility greater than 90%. 
Following, the average raw values were normalized to those of untreated wild-
type homogenate analyzed in the same day.  
For glutamine synthetase activity, frozen tissue from mouse brain cortex 
were processed as described previously (80) with minor modifications.  Briefly, 
cortices were homogenized in 5 volumes of 0.1 M imidazole pH 7.2 using an 
Ultra-Turax homogenizer.  Homogenates were centrifuged at 10000 x g for 10 
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min at 4°C, and the clarified supernatant used for assessing glutamine 
synthetase activity (with protein concentration determined using the Bio-Rad 
Protein Assay).  For UV light exposure to eliminate NO from S-nitrosocysteine, 
part of each sample from wild-type mice was trans-illuminated by UV light while 
on ice for 3 minutes.  Activity was determined in triplicate using 90 μg of clarified 
homogenate in a total volume of 70 μL of reaction buffer (1 mM L-glutamate, 20 
mM ATP, 40 mM MgCl2, 0.1 M hydroxylamine, 0.1 M imidazole pH 7.2), after 
incubation for 20 minutes at 37°C.  The reaction was stopped by the addition of 
190 μL of 0.37 M FeCl3 in 0.67 M HCl/0.2 M TCA, and samples were incubated 
on ice for 5 minutes.  Sample mixtures were then centrifuged at 4 °C for 5 
minutes at 10000 x g, and the absorbance of the resulting supernatant was 
measured at 535 nm and compared to a standard curve of authentic L-
glutamylhydroxamate.  GS activity was expressed as nmol of L-
glutamylhydroxamate per mg of protein per hour. Enzymatic specificity of the 
assay was determined using 0.5 mM L-methionine sulfoximine (MSO) as a 
selective GS inhibitor. 
 For glutamate dehydrogenase activity, frozen forebrain was processed 
using the Mitochondrial Isolation Kit from Sigma-Aldrich.  The final mitochondrial 
pellet was resuspended in mitochondrial resuspension buffer containing 0.32 M 
sucrose, 10 mM Tris-HCI pH 7.4, 0.5 mM EDTA, 0.1% Triton X-100, and protein 
concentration was determined using the Bio-Rad Protein Assay.  Glutamate 
dehydrogenase activity was determined as described previously (81). Briefly, 
activity in the direction of oxidative deamination was assayed in a UV/Vis 
spectrophotometer (HP 8452A, GMI-Inc., Ramsey, MN) at 25°C using 15 μg of 
mitochondrial protein in a final volume of 200 μL of assay buffer (150 mM KCl, 
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0.1 mM rotenone, 20 mM Tris-HCl pH 7.6, 2 mM EGTA, 1 mM NAD+, 2.5 mM 
glutamate).  The velocity of each reaction was calculated from the linear portion 
of the change in NADH absorbance measured at 340 nm.  Enzymatic specificity 
of the assay was determined using 20 μM GTP as a selective GDH inhibitor. 
 For mitochondrial aspartate aminotransferase activity, mitochondrial 
extracts were prepared exactly as described for GDH activity.  Enzymatic activity 
was determined as described previously (82), with minor modifications.  Briefly, 
activity in the direction of α-ketoglutarate production was assayed 
spectrophotometrically using 15 μg of mitochondrial protein in a final volume of 
200 μL of assay buffer (0.02% BSA, 0.1 mM rotenone, 100 mM ADP, 30 mM 
NH4Cl, 120 μM NADPH, 5 mM Glu, 2.5 mM oxaloacetic acid, and 15 μg of 
purified bovine GDH).  The decrease in NADPH absorbance at 340 nm at room 
temperature was followed over 15 minutes and used to calculate the velocity of 
mAspAT activity.  Enzymatic specificity of the assay was determined using 1 mM 
aminooxyacetic acid (AOAA) as a selective mAspAT inhibitor.  
For synaptosomal glutamate uptake, crude synaptosomes were prepared 
from forebrain as previously described (49, 83) with minor modifications.  Briefly, 
animals between 10-12 weeks of age were anesthetized with isoflurane and 
decapitated.  Forebrains from wild-type, nNOS -/-, and eNOS -/- mice was 
dissected and homogenized on ice in 20 volumes of sucrose buffer (0.32 M 
sucrose, 0.1 mM DTPA pH 5.3), while protected from light.  Homogenates were 
centrifuged at 800 x g for 10 minutes at 4°C, and the supernatants were isolated 
for further processing.  Samples from wild-type mice homogenized in sucrose 
buffer without DTPA were also pre-treated at 4°C with 50 μM CuSO4/500 μM 
ascorbate for 30 minutes in the dark to remove NO from  S-nitrosocysteine.  All 
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samples were then centrifuged at 20,000 x g for 20 minutes at 4 °C, and the 
pellets were resuspended in 0.32 M sucrose, 0.1 mM DTPA (pH 5.3).  Samples 
were then centrifuged a final time at 4 °C at 20,000 x g for 20 minutes, with 
pellets finally resuspended in 0.32 M sucrose (pH 5.3).  Sodium-dependent 
transport of L-3[H]glutamate was then measured as described previously (49, 83) 
in the presence or absence of 0.3 mM dihydrokainate (DHK) in order to 
determine DHK-sensitive glutamate uptake (as a measure of excitatory amino 
acid transporter 2 activity). 
Plasmid Constructs 
 Plasmid expressing rat excitatory amino acid transporter 2 was obtained 
from Dr. Baruch Kanner (Hebrew University, Hadassah Medical School, 
Jerusalem, Israel).  The Quikchange Lightning Site-Directed Mutagenesis Kit 
(Agilent Technologies, Santa Clara, CA) was used to introduce single amino acid 
mutations in the transporter as follows.  Cysteine-to-serine mutations were 
introduced using the forward/reverse primer pairs: for Cys373, 5’-
TTGCCTGTCACCTTCCGTAGCTTGGAAGATAATC-3’ and 
5’-GATTATCTTCCAAGCTACGGAAGGTGACAGGCAA-3; and for Cys562,  
5’- ATGGAAAGTCAGCTGACAGCAGTGTTGAGGAAGAA-3’ and 5’- 
TTCTTCCTCAACACTGCTGTCAGCTGACTTTCCAT-3’, resulting in the 
C373S/C562S construct.  All plasmid constructs were verified by sequencing 
prior to use. 
Cell Culture, Transfection, and CysNO Treatment 
 HEK-293T cells were grown in Dulbecco's Modified Eagle Medium 
(DMEM) with Glutamax from Life Technologies (Carlsbad, CA) containing 10% 
fetal bovine serum (FBS), 100 U/mL penicillin, and 100 ng/mL streptomycin, at 
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37°C in air with 5% CO2. Cells were plated at a density of 1.25 × 105 cells/cm2 
and cultured under normal conditions for 24 hours. Cells were transfected with 
wild-type excitatory amino acid transporter 2 (WT GLT1) or the double mutant 
C373S/C562S transporter using the Clontech CalPhos transfection kit (Clontech, 
Mountain View, CA) according to manufacturer’s protocol. At eighteen hours 
post-transfection the growth medium was replaced with serum-free DMEM and 
equilibrated for 2 hours at 37°C.  Afterwards, freshly prepared S-nitrosocysteine 
(CysNO) or cysteine (Cys) was added up to a final concentration of 0.4 mM, and 
cells were incubated for 2 hours.  Cells were extensively washed with PBS, and 
used for measuring glutamate uptake as described previously (84).  Lysates 
were assayed for protein concentration using the Lowry assay and used to 
determine excitatory amino acid transporter 2-mediated glutamate uptake initial 
velocity, described in nmol/mg/min.  For cell surface biotinylation studies, cells 
were processed as described previously (84).  Briefly, after Cys or CysNO 
treatment cell monolayers were washed twice with ice-cold DPBS (pH 7.4) 
containing 0.1 mM CaCl2 and 1.0 mM MgCl2.  Cells were then incubated in 2 mL 
of biotinylation solution (1 mg/mL EZLink Sulfo-NHS-Biotin in DPBS with 0.1 mM 
CaCl2 and 1.0 mM MgCl2) for 30 minutes at 4°C.  The biotinylation solution was 
then aspirated, and excess biotin was quenched by incubating cells with DPBS 
containing 100 mM glycine for 30 minutes at 4°C.  Cells were then lysed in 1 mL 
RIPA buffer with protease inhibitors (1 μg/mL leupeptin, 250 μM 
phenylmethanesulfonyl fluoride, 1 μg/mL aprotinin, and 1 mM iodoacetamide).  
Lysates were then centrifuged to remove cellular debris, and biotinylated proteins 
were batch extracted from the supernatant using UltraLink monomeric avidin 
beads. LDS sample buffer was added to fractions containing total cell lysate, 
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biotinylated proteins (cell surface proteins), and nonbiotinylated proteins 
(intracellular proteins).  Each fraction was diluted and loaded such that the sum 
of immunoreactivity in the nonbiotinylated and biotinylated fractions should equal 
the immunoreactivity found in the lysate, assuming avidin extraction of 
biotinylated proteins is 100%.  For reversibility studies, uptake was studied in 
cells at 0, 60, 120 and 240 minutes after the removal of CysNO.  Additionally, 
lysates from each treatment condition were processed in parallel as previously 
described (28-30) for S-nitrosoprotein enrichment and subsequent Western blot 
detection of S-nitrosylated excitatory amino acid transporter 2. 
Molecular Modeling of the Effects of S-nitrosylation 
The 2.4Å resolution crystal structure of mitochondrial aspartate 
aminotransferase was taken from PDB 3PD6 (53). The 2.7Å resolution crystal 
structure of human glutamate dehydrogenase was taken from PDB 1L1F (54). 
The 2.6Å resolution crystal structure of human glutamine synthetase was taken 
from PDB 2QC8 (55).  Structures of mAspAT with S-nitrosyl modified cysteine 
(SNC) at positions 106 and 295, GDH with SNC at position 59 (equivalent to 
position 112 in the mouse sequence) and GS with SNC at positions 99, 183, 269 
and 346 were built using VMD and a custom SNC residue template (56). 
Electrostatic potentials from the cysteine or SNC residues were calculated using 
the finite difference Poisson-Boltzmann method as described previously (57-58). 
The solvent was assigned a dielectric of 78.6 and an ionic strength of 145 mM. 
The protein was assigned a dielectric of 2. Partial atomic charges for the 
unmodified cysteine residue were taken from the CHARMM27 molecular 
mechanics forcefield (59). Atomic charges for SNC were obtained from 
electronegativity neutralization using the program QEQUIL (60), giving +0.35 
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(CβH2), -0.17 (Sγ), +0.06 (Nδ), and -0.24 (Oε), in atomic charge units. Structures 
and potentials were visualized using PyMol (61). 
Statistical analysis 
Data were analyzed with GraphPad Prism 5.0d software. All normally 
distributed data were displayed as means ± SE. Groups were analyzed by one- 
or two-way analysis of variance (ANOVA), with appropriate post-hoc tests. 
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4.1 Summary 
 S-nitrosylation has gained prominence in recent years as a major 
mechanism for the˙NO-dependent regulation of structure and function for 
individual proteins.  However, much is still unknown regarding how this 
posttranslational modification may coordinate diverse biological processes in 
response to specific stimuli.  For this thesis, we uncovered multiple protein 
targets of physiological S-nitrosylation in the mouse that rely on either nNOS-
derived or eNOS-derived ˙NO for detection, and demonstrate a role for nNOS in 
the regulation of the glutamate/glutamine cycle during excitatory 
neurotransmission.  In the process, we took advantage of the plethora of data 
available from our proteomic studies to generate hypotheses that were tested 
using a variety of metabolomic, biochemical, and molecular biology approaches. 
4.2 The necessity of mass spectrometry-based proteomic approaches 
in comprehensively studying biological change 
 Proteomic methodologies represent a powerful addition to other global 
interrogations of cellular response, including genomic and transcriptomic 
screens.  In particular, their ability to identify proteins from complex mixtures 
(when coupled to upstream chromatographic separation techniques) makes MS-
based proteomics a toolset of choice for many cell signaling studies.  The value 
of this work can be further enhanced with the use of various complementary 
approaches, including stable isotopic labeling-based protein quantification and/or 
selective enrichment techniques available for specific posttranslational 
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modifications.  Despite these advances, the depth of proteomic analysis is still 
limited in comparison to published genomic screens: in humans, only ~84% of 
protein-coding genes identified in the genome have been matched to proteins 
detected by MS1.  This gap will narrow in the coming years, however, with 
refinements in both genome annotation and proteomic methodologies.  
Regardless of this caveat, MS-based proteome analysis still represents the most 
useful route for investigating global changes in protein homeostasis that 
accompany given physiological stimuli, and can generate the preliminary 
information needed for more targeted hypotheses of biological function. 
 Application of our protocol for S-nitrosoprotein enrichment and subsequent 
LC-MS/MS analysis to the wild-type mouse brain yielded the most 
comprehensive physiological S-nitrosoproteome currently available for this 
organ, with an improvement of 225 additional sites and 92 additional protein 
targets over previous reports.  Comparison of this dataset to those we obtained 
from nNOS-/- and eNOS-/- brain allowed us to make hypotheses about the 
contributions of nNOS-derived ˙NO to normal CNS function, and afforded the 
opportunity to explore them in more detail using traditional biochemistry and 
molecular biology approaches.  In doing so, we provided evidence for S-
nitrosylation as a global regulator of synaptic transmission through its regulation 
of glutamate availability, and offered a prime example for the importance of MS-
based proteomics in leading to focused mechanistic studies. 
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4.3 Systemic regulation of brain physiology by S-nitrosylation 
 Our work uncovered 136 protein targets of S-nitrosylation in the wild-type 
mouse brain.  Subsequent gene ontology analysis revealed 6 of these proteins to 
be directly involved in glutamate/GABA metabolism and the glutamate/glutamine 
cycle, with 4 proteins further scrutinized for S-nitrosylation-dependent regulation 
of glutamate oxidation/transport/recycling to glutamine.  Intriguingly, we also 
found an additional 29 proteins that participate in various stages of cellular 
metabolism, including glycolysis (Figure 1), the tricarboxylic acid (TCA) cycle 
(Figure 2), and oxidative phosphorylation (Table 1).  Each of these processes 
indirectly contributes to steady-state levels of glutamate, principally through 
regulation of the synthesis or consumption of its 5-carbon backbone.  Curiously, 
some proteins from each pathway were found to be S-nitrosylated in WT, eNOS-/-
, and nNOS-/- brain, suggesting one or both of the following possibilities: 1) 
redundancy between eNOS- and nNOS-derived ˙NO in modifying said protein(s), 
or 2) ˙NO from another source common to all genotypes (such as iNOS) was 
utilized instead.  Conversely, a few proteins from each pathway were only 
observed in the WT brain, suggesting that for them both eNOS- and nNOS-
derived ˙NO may be necessary to modify enough protein to be detected by our 
method.  Regardless, given the significant convergence between S-nitrosylation, 
metabolism, and excitatory neurotransmission, a role for eNOS- and/or nNOS-
derived ˙NO in coordinating the latter two processes is a strong possibility.  
117 
 
 
Figure 4.1: S-Nitrosylation in Glycolysis.  Multiple enzymes involved in the synthesis and metabolism of glycolytic 
substrates are modified by cysteine S-nitrosylation.  1) Enzymes denoted in blue had detectable S-nitrosocysteine 
residues in wild-type and nNOS-/- brain, but not eNOS-/- (eNOS-dependent).  2) Those denoted in red had detectable S-
nitrosocysteine residues in wild-type and eNOS-/- brain, but not nNOS-/- (nNOS-dependent).  3) Those denoted in green 
had detectable S-nitrosocysteines in wild-type, nNOS-/-, and eNOS-/- brain (suggesting redundancy between nNOS and 
eNOS, or possibly iNOS dependence).  4) Those denoted in yellow were only found to be modified in wild-type brain, not 
nNOS-/- or eNOS-/- (require both isoforms).  5) Those denoted in black were not detectable as S-nitrosylated in any 
genotype. 
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Figure 4.2: S-Nitrosylation in the Tricarboxylic Acid Cycle.  Several enzymes in the TCA cycle are modified by 
cysteine S-nitrosylation.  1) Enzymes denoted in blue had detectable S-nitrosocysteine residues in wild-type and nNOS-/- 
brain, but not eNOS-/- (eNOS-dependent).  2) Those denoted in red had detectable S-nitrosocysteine residues in wild-type 
and eNOS-/- brain, but not nNOS-/- (nNOS-dependent).  3) Those denoted in green had detectable S-nitrosocysteines in 
wild-type, nNOS-/-, and eNOS-/- brain.  4) Those denoted in yellow were only found to be modified in wild-type brain, not 
nNOS-/- or eNOS-/- (suggesting redundancy between nNOS and eNOS, or possibly iNOS-dependent ).  5) Those denoted 
in black were not detectable as S-nitrosylated in any genotype. 
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Table 4.1: S-Nitrosylated Proteins in Oxidative Phosphorylation.  At least one protein in each of the 4 major 
complexes of the electron transport chain contains S-nitrosocysteines that were detected in the wild-type mouse brain.  S-
nitrosoprotein targets are denoted above, along with the genotypes in which they were observed. 
Protein Name Uniprot ID WT eNOS-/- nNOS-/- 
NADH 
dehydrogenase 
[ubiquinone] iron-
sulfur protein 6, 
mitocondrial 
(Complex I) 
P52503 X X X 
Succinate 
dehydrogenase 
[ubiquinone] 
flavoprotein 
subunit, 
mitochondrial 
(Complex II) 
Q8K2B3 X X X 
Electron transfer 
flavoprotein-
ubiquinone 
oxidoreductase, 
mitocondrial 
(Complex II) 
Q921G7 X   
Cytochrome b-c1 
complex subunit 6, 
mitochondrial* 
(Complex III) 
P99028 X X  
Cytochrome c1, 
heme protein, 
mitochondrial 
(Complex III) 
Q9D0M3 X   
Cytochrome c 
oxidase subunit 5B, 
mitochondrial* 
(Complex IV) 
P19536 X X X 
ADP/ATP 
translocase 1 
P48962 X   
ATP synthase 
subunit alpha, 
mitochondrial 
Q03265 X   
ATP synthase 
subunit gamma, 
mitochondrial 
Q91VR2 X X  
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 Many of the emergent concepts of ˙NO-dependent metabolic control found 
in our work are supported by previous reports. eNOS-derived ˙NO from 
endothelial cells has been shown to increase aerobic glycolysis and lactate 
production in astrocytes in co-cultures via HIF-1α-mediated transcription2, a 
result reinforced by earlier studies documenting elevated astrocytic glycolysis 
after treatment with ˙NO donors3-4.  Such effects on glucose metabolism may at 
least in part be explained by our proteomic analyses, which found eNOS-
dependent S-nitrosylation of enzymes responsible for the first steps of glucose 
phosphorylation (Figure 1).  Our identification of nNOS-dependent S-nitrosylation 
of inositol-3-phosphate synthase 1 and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) in the brain (Figure 1) also suggests an a role for 
nNOS-derived ˙NO in the regulation of glycolysis, with nNOS-dependent GAPDH 
S-nitrosylation validated by previous studies5-6.  Additionally, NMDA receptor-
dependent activation of nNOS has been associated with inhibition of the TCA 
cycle in rat striatum7, an observation consistent with both the increased 
glutamate oxidation8 and reduced numbers of S-nitrosocysteine residues in TCA 
cycle enzymes we identified in nNOS-/- brain (Figure 2).  However, though 
differences exist between eNOS-derived and nNOS-derived S-nitrosylation in 
their respective protein targets, it may very be that both NOS isoforms are used 
to coordinate the large-scale shifts in metabolism necessary to support changes 
in synaptic plasticity. 
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 Taking into account the intimate links that we and others have established 
between the glutamate/glutamine cycle8, glucose metabolism9, and synaptic 
plasticity10, one can appreciate the metabolic support necessary for long-term 
changes in excitatory neurotransmission.  Based on the data presented herein, 
nitric oxide may act as a mediator between these biological processes via 
specific NOS isoform-dependent S-nitrosylation of key effector proteins in each 
cellular pathway.  Moreover, in lieu of the regulatory contributions of this 
posttranslational modification to glutamate availability, the developmental 
significance of nNOS-derived ˙NO11-16 can be better understood. 
4.4 Implications and future directions 
 The results of this study, as well as those of other groups17-21, reinforce 
the vital influence of nNOS-derived ˙NO in glutamatergic transmission.  Our data 
suggests that at least part of this ˙NO-dependent regulation is achieved through 
the S-nitrosylation of key proteins involved in glutamate transport, oxidation, and 
recycling to glutamine.  Still, the relevance of this phenomenon to multiple 
aspects of neurobiology, including plasticity, development and 
neurodegeneration, is yet to be explored. 
4.4.1 Stoichiometry 
 Our findings revealed that roughly 8-25% of all molecules for each of the 
four proteins studied (GLT1, GDH, mAspAT, and GS) were modified by S-
nitrosylation8, values that are in line with those described for other enzymes22.  At 
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first glance, these numbers appear incongruous with the changes in protein 
activity observed between wild-type and nNOS-/- brain (or after S-nitrosothiol 
elimination in wild-type extracts): GLT1, GDH, and mAspAT function was 
inhibited by 20-80% when S-nitrosylated in vivo, while GS activity was decreased 
by 40% upon S-nitrosothiol elimination8.  However, each of the four proteins in 
question assemble into multimeric complexes: GLT1 as a trimer23 , GDH as a 
hexamer24 , mAspAT as a tetramer25 , and GS as a decamer26 .  Given this 
information, S-nitrosylation of one or more monomers in each multimer may act 
in a dominant-negative (for GLT1, GDH, and mAspAT) or dominant-positive 
manner (for GS) in regulating protein function.  Such a concept is further 
reinforced by our molecular modeling studies of the modification for GDH, 
mAspAT, and GS, which revealed that S-nitrosylation of the cysteines identified 
in vivo generates a repulsive electrostatic wedge between subunits that could 
plausibly drive allosteric regulation of protein function8. 
Stoichiometric studies of posttranslational modifications traditionally rely 
on the substitution of modified amino acids in proteins with “mimetics,” such as 
aspartate/glutamate (for phosphoserine/phosphothreonine27) or glutamine (for 
acetyllysine28).  On the other hand, such an approach has not been as robustly 
validated for protein S-nitrosocysteine residues: several groups have attempted 
to do so through replacement of cysteine residues with alanine29 or tryptophan30  
in order to recapitulate the effects of S-nitrosylation, with mixed results.  Still, 
coexpression of “nitrosomimetic” Cys-to-Ala/Cys-to-Trp mutant proteins with non-
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nitrosylatable Cys-to-Ser mutants (which, at least for GLT1, have been shown to 
have comparable basal activity to the wild-type protein8) may be worth 
investigating in order to ask how the stoichiometry of S-nitrosylation relates to its 
effects on protein function in vitro and in vivo. 
4.4.2 Spatiotemporal Regulation of Nitric Oxide and S-Nitrosylation in 
Synaptic Plasticity 
 Most of our analyses of S-nitrosylation and its effects on protein function 
were performed in samples from 8-12 week old mice of WT, nNOS-/-, and eNOS-/- 
genotypes.  In doing so, we measured enzyme and transporter activity in the 
presence of steady-state levels of S-nitrosylation established during CNS 
development in these animals.  Because of this, it is natural to wonder about the 
on/off kinetics of the modification and its effects on glutamate/glutamine 
metabolism, particularly within time scales used for monitoring acute changes in 
synaptic function (milliseconds to seconds) and synaptic plasticity (minutes to 
hours).  Unfortunately, it is not currently possible to detect changes in protein S-
nitrosylation within the short periods of time used for measuring acute changes in 
synaptic function.  Despite this limitation, however, conclusions can still be made 
about the roles of ˙NO and S-nitrosylation in supporting synaptic plasticity. 
 Several long-term changes in plasticity (i.e. in long-term potentiation) 
occur minutes to hours after the initial paired presynaptic/postsynaptic tetanic 
stimuli31. ˙NO-dependent signaling is thought to augment this process, rather 
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than acting alone as a retrograde neurotransmitter32.  Moreover, within a similar 
period of time following stimulation, ˙NO diffuses over a radius of 100-200 μm 
from its postsynaptic source19,33, allowing it to reach multiple cellular 
compartments of the tripartite synapse. Given that our analyses8 of 
glutamine/glutamate utilization (via metabolomics) and S-nitrosylation reversibility 
(in vitro) was performed within similarly relevant time periods (minutes to hours 
following chemical stimulation or S-nitrosocysteine treatment), the data we 
obtained points toward S-nitrosylation as more of a long-term regulator of 
synaptic plasticity rather than a short-term affector of synaptic function.  This 
finding is reinforced by previous reports from other groups, which have 
documented differences in S-nitrosylation and function of specific proteins within 
a period of minutes to hours following stimulation34-36. 
4.4.3 Therapeutic Implications in Neurological Disorders 
 Neuronal nitric oxide participates in several processes during CNS 
maturation, including neurogenesis37-41, excitatory synapse development42-43, 
neuronal migration44 and differentiation37.  In light of the reciprocity between 
glutamate metabolism and synaptic activity10, as well as our own data, it may be 
that nNOS-derived protein S-nitrosylation contributes to the synapse-pruning 
events underlying the developmental transition between the juvenile and adult 
brain45-46.  Mechanistically, this may be accomplished by facilitating spatially 
restricted elevations of extracellular glutamate to strengthen specific synapses, 
while weakening others by allowing astrocytic glutamate removal and 
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subsequent oxidation.  Additionally, alterations in these events could play a role 
in aberrant neurological disorders such as schizophrenia, autism spectrum 
disorder (ASD), and epilepsy due to changes in nNOS expression and its 
associated synthesis of ˙NO47-51.  The study of these processes in a 
developmental context is worthy of further inquiry, and may lead to novel 
therapeutic avenues for specific diseases in the CNS. 
 Several forms of neurodegeneration exhibit evidence of glutamate-
dependent excitotoxicity, including Alzheimer’s disease52 (AD), Parkinson’s 
disease53 (PD), stroke54, and traumatic brain injury55 (TBI).  One common 
component of pathological progression in these diseases is the increased 
synthesis of ˙NO by nNOS, which in some cases is subsequently followed by the 
S-nitrosylation of specific proteins that contribute to cell death56.  In particular, 
genetic deletion or inhibition of nNOS in rodents is neuroprotective following 
cerebral ischemia, MPTP treatment, or TBI11,57-61.  Our results may provide an 
explanation for this effect, by implicating nNOS-derived protein S-nitrosylation in 
generating the excessive synaptic glutamate concentrations necessary for 
downstream excitotoxic events.  If this is the case, one way to potentially 
ameliorate these deleterious effects is to administer branched-chain amino acids 
(BCAAs): these supplements can allosterically activate glutamate 
dehydrogenase62, leading to increased glutamate oxidation and, as a corollary, 
decreased glutamate availability for excitotoxic processes.  BCAA administration 
has already been shown promote cognitive rehabilitation after TBI in rodents63-64, 
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and may promote a similar recovery following ischemia or other forms of 
neurodegeneration.  However, the perturbation of this pathway under such 
conditions needs to be confirmed before alternative therapeutic options are 
considered.  
The data presented in this work provides compelling evidence for nNOS-
derived protein S-nitrosylation in the regulation of synaptic glutamate levels 
during normal function in the CNS.   By extending its findings to additional 
physiological and non-physiological paradigms, we can ask more detailed 
questions about the functional relevance in synaptic activity, as well as whether 
aberrant ˙NO-dependent regulation of glutamate metabolism plays a role in the 
pathological progression of different neurological disorders.  Furthermore, in 
doing so we can explore opportunities for therapeutic intervention that focus on 
either nNOS (as has been done for ischemia65) or specific steps of 
glutamate/glutamine metabolism.  
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